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  The fundamental importance of the central serotonergic system is reflected in 
the extensive innervation of brain areas by serotonin (5-HT) nerve fibers and the 
diversity of the serotonin receptor family. To date, seven 5-HT receptor families 
with 14 different receptor subtypes are identified. Detailed research on each of the 
different subtypes is necessary to understand the complexity of the serotonergic 
system and the functional role of the different receptor subtypes. Dysfunction of 
the central serotonergic system has been implicated in the pathophysiology of 
several psychiatric disorders. The serotonergic system is an important target in 
the treatment of psychiatric disorders like schizophrenia, depression and anxiety. 
Selective 5-HT reuptake inhibitors (SSRIs) are drugs that enhance 5-HT levels by 
preventing the reuptake of 5-HT. SSRIs were introduced in the 1980s and since 
then widely used in the treatment of depression and some anxiety disorders. A 
major clinical problem is, however, that it requires several weeks before a 
therapeutic effect is achieved. This delayed onset of action suggests that adaptive 
changes occur. Pre-clinical studies indicated a role of 5-HT autoreceptors in the 
delayed of action of SSRIs. 5-HT1B receptors are present in the brain both as 
autoreceptors, controlling the release of 5-HT at serotonergic nerve terminals, and 
as heteroreceptors modulating other neurotransmitters, suggesting that this 
receptor is involved in a variety of functions. Therefore, 5-HT1B receptors may be a 
potential target to augment treatment with SSRIs. Moreover, dysfunction of 5-HT1B 
receptors has been associated with aggression, impulsivity, alcoholism and drug 
abuse. More insight in the functional role of 5-HT1B receptors contributes to our 
understanding of this receptor subtype in 5-HT neurotransmission and in its role in 
psychiatric disorders. 
 
 
Central serotonergic system 
 
Serotonergic innervation of the forebrain 
In the 1950s, the existence of 5-HT in the mammalian brain was first reported 
(Twarog and Page, 1953). Serotonin is a bioamine and is synthesized from 
tryptophan, an amino acid originating from the diet. Cell bodies containing 5-HT 
are located in nine discrete cell clusters, located near the midline of the brainstem 
(Dahlstrom and Fuxe, 1964). The most caudal raphe nuclei project mainly to the 
gray matter of the spinal cord, while the 5-HT neurons innervating the forebrain 
mainly originate in the dorsal raphe nucleus (DRN) and median raphe nucleus 
(MRN). The 5-HT cells in the raphe nuclei innervate virtually all forebrain areas 
(Steinbusch, 1981) as shown in Figure 1. The DRN is the most extensively 
studied and is the larger nucleus with about 11,500 serotonergic cells, and the 
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MRN contains about 1100 serotonergic cells. The serotonergic system appears 
similar in primates and non-primates in the distribution of 5-HT cell bodies and 
their projection network (Jacobs and Azmitia, 1992). In primates, however, the 
raphe nuclei are more laterally localised and the DRN is more highly organized. 
Both neuroanatomical and functional mapping studies have indicated that the 
projections from the DRN and MRN have distinct patterns of distribution, with 
some forebrain areas receiving mixed innervation of these nuclei and others 
receiving relatively selective DRN or MRN inputs. For example, the frontal cortex 
and striatum appear to be predominantly innervated by the DRN, while the dorsal 
part of the hippocampus is rather exclusively innervated by the MRN and the 
ventral hippocampus receives mixed input from both DRN and MRN (see Jacobs 
and Azmitia, 1992, McQuade and Sharp, 1997). Moreover, serotonergic 
connections between the raphe nuclei exist. The main source of 5-HT fibers 
reaching the DRN arises either from the DRN itself or from the MRN (Jacobs and 
Azmitia, 1992). Inputs to the DRN arise from many sources, from the locus 
coeruleus (noradrenergic), the substantia nigra (dopaminergic), periaqueductal 
gray (neuropeptides), the hypothalamus, and the lateral habenula (see Jacobs 
and Azmitia, 1992). The DRN also receives input from the medial prefrontal cortex 
(mPFC), other cortical areas and hypothalamic nuclei (Hajos et al., 1999, Peyron 
et al., 1998).  
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic drawing of the location of the serotonergic nuclei (B1-B9) and
their major projections in the brain. B7: dorsal raphe nucleus, B8: median raphe
nucleus, 3V: third ventricle, CB: cerebellum, cc: corpus callosum, CPu: caudate
putamen, GP: globus pallidus, H: hypothalamus, Hip: hippocampus, Ic: inferior
colliculus, LS: lateral septum nuclei, mfb: medial forebrain bundle, mm: mammillary
nucleus, OB: olfactory bulb, oc: optic chiasma, OT: olfactory tubercle, Pit: pituitary, Sc:
superior colliculus, SN: substantia nigra, T: thalamus.   Adopted from H. Sijbesma
(thesis 1991). 
4 | CHAPTER 1 
5-HT receptors 
5-HT exerts its function through activation of different receptor subtypes. To date, 
seven different 5-HT receptor families (5-HT1-7) with 14 subtypes are identified. 
The 5-HT receptors are classified as 5-HT1A,1B,1D,1E,1F, 5-HT2A,2B,2C, 5-HT3, 5-HT4, 
5-HT5A,5B, 5-HT6 and 5-HT7 (Hoyer et al., 1994, Barnes and Sharp, 1999). The 5-
HT receptor subtypes display a distinct pattern of distribution within the CNS. 5-
HT receptors are all G-protein coupled receptors, except 5-HT3 receptors, which 
are ion channel coupled. In this chapter 5-HT1 receptors will be discussed, details 
on other 5-HT receptor subtypes and their function can be found in recent review 
(Barnes and Sharp, 1999).  
 
 
Regulation of 5-HT neurotransmission 
 
5-HT1A autoreceptors 
5-HT is released at nerve terminals through exocytosis, triggered by action 
potential induced depolarisation. Presynaptically located 5-HT transporters 
terminate the action of 5-HT (see box 1). After reuptake, extravesicular 5-HT is 
deaminated by mono-oxidase (MAO), and subsequently oxidated by aldehyde 
dehydrogenase to its metabolite 5-HIAA. Electrophysiological studies have 
demonstrated that the neuronal activity of raphe cells is inhibited by 5-HT 
sensitive receptors on the cell bodies and dendrites of serotonergic cells in the 
raphe nuclei (Sprouse and Aghajanian, 1987). Activation of these receptors 
results in inhibition of neuronal activity, and subsequent in diminished 5-HT 
release at the nerve terminals. It is well known that somatodendritic autoreceptors 
are of the 5-HT1A receptor subtype. Selective drugs for 5-HT1A receptors, like 8-
OH-DPAT, have been found to inhibit raphe cell firing (Sprouse and Aghajanian, 
1987, Arborelius et al., 1995). In vivo microdialysis studies have clearly shown 
that activation of 5-HT1A receptors decreases output of 5-HT in several brain 
areas, including the dorsal and median raphe nuclei, frontal cortex, hippocampus 
and striatum and amygdala (Hjorth and Sharp, 1991, Bosker et al., 1996, Bosker 
et al., 1997a). Moreover, raphe 5-HT neurons may be controlled through 
postsynaptic 5-HT1A receptors located in the mPFC (Hajos et al., 1999, 
Casanovas et al., 1999) and in the amygdala (Bosker et al., 1997b). This long 
feedback loop may be restricted to specific serotonergic projection areas, since 
activation of 5-HT1A receptors in the hippocampus, a brain structure rich in 5-HT1A 
receptors, has no effect on 5-HT release in this brain area (Kreiss and Lucki, 
1994).  
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What is the source of 5-HT in the raphe nuclei? Ultrastructural studies reported 
that axon terminals are observed in the raphe nuclei, but only few terminals make 
synaptic contacts (Jacobs and Azmitia, 1992). Extracellular 5-HT levels are twice 
as high in the raphe nuclei as in 5-HT projection areas (Bel and Artigas, 1992). 
Therefore it is thought that the source of 5-HT in the raphe is mainly from 
somatodendritic origin, and differs from the 5-HT release at nerve terminals in the 
projection areas (see Pineyro and Blier, 1999). Nevertheless, stimulation of these 
receptors by locally applied 5-HT1A receptor agonists reduces 5-HT output in the 
raphe nuclei, indicating that extracellular 5-HT in the DRN and MRN is modulated 
by somatodendritic 5-HT1A autoreceptors (Adell et al., 1993, Bosker et al., 1994, 
Bosker et al., 1996). 
 
5-HT1B autoreceptors 
On serotonergic nerve terminals, the release of 5-HT is controlled by inhibitory 5-
HT1B autoreceptors. In vitro release studies indicated the existence of a terminal 
autoreceptor of the 5-HT1B receptor subtype (Engel et al., 1986, Maura et al., 
1986, Hoyer and Middlemiss, 1989). The negative feedback on 5-HT output by 5-
HT1B autoreceptors was supported by in vivo microdialysis studies using local 
administration of the 5-HT1B receptor agonist CP93129, a compound that does not 
cross the blood-brain barrier, into different brain structures, including the 
hippocampus and the frontal cortex (Hjorth and Tao, 1991, Bosker et al., 1995, 
Adell et al., 2001). Interestingly, an in vivo electrophysiology study in mice 
demonstrated that stimulation of 5-HT1B receptors following intravenous applied 
CP94253, a centrally active compound, increased firing rate of dorsal raphe 5-HT 
neurons (Evrard et al., 1999). This was unexpected, as previous studies 
performed in rat found no evidence for such an excitatory control of DRN neuron 
firing activity through 5-HT1B receptors (Sprouse et al., 1997). Nevertheless, a 
microdialysis study in rats indicated that stimulation of 5-HT1B receptors by 
CP93129 reduced 5-HT release in the DRN and even more markedly in the MNR 
(Adell et al., 2001). These findings are supported by a voltammetry study showing 
that CP93129 reduced 5-HT release both in the DRN and MRN (Hopwood and 
Stamford, 2001). The intravenous administration of CP94253 to anaesthetised 
rats did not affect DRN 5-HT neurons, but showed a biphasic effect on the firing 
rate of MNR causing an increase after a high dose and decrease after lower 
doses of CP94253 (Adell et al., 2001). The localisation of 5-HT1B receptors in the 
raphe is not completely clear, but is presumably on 5-HT nerve terminals. 
Autoradiographic studies demonstrated binding of 5-HT1B receptors in the raphe 
nuclei (Boschert et al., 1994), while 5-HT1B-like immunoreactivity could not  be 
6 | CHAPTER 1 
 
Box 1.  Volume neurotransmission 
Ultrastructural analysis of the serotonergic system demonstrated that 5-HT 
neurotransmission is predominantly non-synaptic (Bunin and Wightman, 1999). 
Neurotransmission through synaptic junctions, or wiring transmission, is the 
classic concept of a neurotransmitter, which is released by exocytosis into the 
synaptic cleft, activates postsynaptic receptors, and subsequent the 
neurotransmitter is removed from the synaptic cleft by reuptake sites. Volume 
neurotransmission, also referred to as paracrine or non-synaptic 
neurotransmission, can occur when receptors are located extrasynaptically and 
if released neurotransmitter reaches the extrasynaptic space at sufficiently high 
concentrations to activate its receptor (Zoli et al., 1999). It has been reported 
that 5-HT systems have a great spillover of 5-HT out of the synaptic junction 
(Bunin and Wightman, 1998). Consistent with the notion of volume 
neurotransmission, 5-HT transporters have been demonstrated along 5-HT cell 
axons and perisynaptic area, suggesting a broad range of 5-HT uptake sites 
beyond synaptic junctions in rat brain (Pickel and Chan, 1999, Tao-Cheng and 
Zhou, 1999). Furthermore, 5-HT1A and 5-HT1B receptors predominate at 
extrasynaptic and nonsynaptic sites (Boulenguez et al., 1996, Sari et al., 1999, 
Riad et al., 2000). In the DRN, some 5-HT varicosities are junctional, but most 
are non-junctional (Chazal and Ralston, 1987). In most 5-HT projections areas, 
for example in the frontal cortex, hippocampus and neostriatum, varicosities are 
also predominantly non-junctional, whereas, for example in the substantia nigra 
(SN) pars reticulata almost all varicosities are of the junctional type (Moukhles 
et al., 1997). The relative frequency of junctional and non-junctional synaptic 
contacts in different 5-HT projection areas indicates region specific actions of 5-
HT. Moreover, the non-junctional network of most 5-HT projection areas is in 
line with the general view that 5-HT acts as a global modulatory system. 
 
 
detected in the raphe (Sari et al., 1999). Taken together, these findings suggest 
that 5-HT1B receptors localised in the MRN may affect 5-HT release. In addition to 
5-HT1A and 5-HT1B autoreceptors, there is substantial evidence that 5-HT1D 
receptors localised in the DRN may act as autoreceptors controlling the release of 
5-HT (Pineyro et al., 1995a;Pineyro et al., 1996, Starkey and Skingle, 1994, 
Davidson and Stamford, 2000, Moret and Briley, 1997). Why are multiple 5-HT1 
receptor subtypes needed for the autoregulation of 5-HT? It has been suggested 
that 5-HT1A, 5-HT1B and 5-HT1D receptors, each different located, may have 
different roles in controlling 5-HT release (Stamford et al., 2000).  
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5-HT1B receptors 
 
Species differences 
Literature on 5-HT1B receptors is sometimes confusing due to the use of old 
nomenclature. Originally, 5-HT1B receptors were found in species like rat, hamster, 
mouse, and opossum, while 5-HT1Dß receptors were found in human, guinea pig, 
cow and dog. Cloning of the mouse 5-HT1B receptor (Voigt et al., 1991, Adham et 
al., 1992 , Maroteaux et al., 1992) revealed a  high homology of 96% in the 
transmembrane domain with the 5-HT1Dß receptor (Jin et al., 1992) . The receptors 
are considered as species homologues and are now classified as r5-HT1B and h5-
HT1B receptors (Hartig et al., 1996). Despite the high homology, rodent 5-HT1B 
receptors bind certain ß-adrenoceptor antagonists, such as propranolol and 
pindolol, with a much higher affinity than human 5-HT1B receptors (Adham et al., 
1994). This pharmacological difference is due to only one amino acid difference in 
the seventh transmembrane domain of the receptor (Oksenberg et al., 1992). For 
intracellular signal transduction, 5-HT1B receptors (like all 5-HT1 receptors) are 
negatively coupled to adenylate cyclase through Gi/o proteins (Adham et al., 
1992). 
 
Distribution 
5-HT1B receptors are expressed throughout the brain, the highest binding 
densities are found in the basal ganglia, substantia nigra, globus pallidus, and 
moderate binding densities in the striatum, cortical areas, hippocampal areas, 
thalamic nuclei and deep cerebellar nuclei (Maroteaux et al., 1992, Bruinvels et 
al., 1993, Sari et al., 1999). In both the DRN and MRN, mRNA for 5-HT1B 
receptors was detected, and 5-HT1B receptor mRNA levels were markedly 
reduced following lesion of the serotonergic system, indicating that 5-HT1B 
receptors are synthesised in serotonergic neurons within the raphe nuclei (Doucet 
et al., 1995). 
But not in all projection areas where binding sites for 5-HT1B receptors are 
demonstrated, mRNA for this receptor could be detected. This mismatch between 
binding sites and mRNA of 5-HT1B receptors, combined with lesion studies, 
indicated that 5-HT1B receptors are present as presynaptic receptors, both on 
serotonergic and non-serotonergic nerve terminals (Boschert et al., 1994). For 
example, in the substantia nigra high binding densities are found, but no mRNA 
for 5-HT1B receptors, while in the striatum, the projection area of the SN, both 5-
HT1B receptors binding sites and mRNA was demonstrated. Taken together, this 
mismatch indicated that 5-HT1B receptors are present on projection neurons from 
to striatum to the substantia nigra. 
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Pharmacology 
Research on 5-HT1B receptors has been complicated because most available 
ligands are not selective (see Hoyer et al., 1994). The most potent agonists 
include CP93129, CP94253, RU24969, 5-CT and a potent antagonist is 
methiothepin, but all these compounds also have (some) affinity for other 5-HT 
receptor subtypes, particularly for 5-HT1A receptors (Barnes and Sharp, 1999). For 
example, CP93129 is a potent agonist with a 200 times greater selectivity for 5-
HT1B than for 5-HT1A receptors (Macor et al., 1990). A more selective 5-HT1B 
receptor antagonist is GR127935, although this compound does not discriminate 
between 5-HT1B and 5-HT1D receptors (Skingle et al., 1995). SB224289, is also a 
selective 5-HT1B receptor antagonist (Gaster et al., 1998). Both GR127935 and 
SB224289 are selective antagonists for both rodent and human 5-HT1B receptors, 
but these compounds have been found to display partial agonistic properties at 
h5-HT1B and 5-HT1D receptors in vitro, although there is no in vivo evidence for 
such properties (Pauwels, 1997, Millan et al., 1999). As outlined above, there is a 
pharmacological difference between human and rodent 5-HT1B receptors. 
Recently, a new selective rodent 5-HT1B receptor antagonist, NAS-181, has come 
available that has been shown to enhance 5-HT synthesis and metabolism (Berg 
et al., 1998, Stenfors et al., 2000).  
Interestingly, 5-HT moduline, an endogenous peptide has been discovered that 
was found to interact with 5-HT1B receptors in a non-competitive inhibitory way 
(Massot et al., 1996, Rousselle et al., 1998). In mice lacking 5-HT1B receptors 
binding of 5-HT moduline is absent, indicating that the 5-HT1B receptor is the 
specific target for this peptide (Cloez-Tayarani et al., 1997). 5-HT moduline 
appears capable of altering the reactivity of 5-HT1B receptors making it less 
sensitive to an agonist. Behavioural studies suggest that 5-HT moduline may be 
involved in conditions related to anxiety and stress (Grimaldi et al., 1999, 
Chennaoui et al., 2000). 
 
5-HT1B heteroreceptors  
Studies in hippocampal synaptosomes have indicated a modulatory role of 5-HT1B 
receptors in acetylcholine release (Maura et al., 1986, Bolanos-Jimenez et al., 
1995, Sarhan and Fillion, 1999). Furthermore, a microdialysis study has 
demonstrated an increase of acetylcholine levels following 5-HT1B receptor 
stimulation with CP93129 in the frontal cortex (Consolo et al., 1996). In the dorsal 
subiculum, glutamate release has been reported to be inhibited through 5-HT1B 
receptors localised in the CA1 area of the hippocampus (Boeijinga and Boddeke, 
1993, Ait Amara et al., 2001). Microdialysis studies have shown that stimulation of 
5-HT1B receptors with locally applied CP93129 results in increased dopamine (DA) 
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levels in the striatum (Galloway et al., 1993, Benloucif et al., 1993), in the 
prefrontal cortex (Iyer and Bradberry, 1996), and in the nucleus accumbens (Yan 
and Yan, 2001). Effects mediated by 5-HT1B receptors are general inhibitory in 
nature, thus the increases of DA observed following 5-HT1B receptor stimulation 
are presumably indirectly mediated effects. Electrophysiological studies have 
reported that activation of 5-HT1B receptors inhibits the release of GABA from 
terminals that innervate DA neurons in the substantia nigra and the ventral 
tegmental area, resulting in disinhibition of DA neurons (Johnson et al., 1992, 
Cameron and Williams, 1994, Morikawa et al., 2000).  
 
Behavioural pharmacology 
Most studies on the behavioural effects of 5-HT1B receptor stimulation, compared 
the effects of 5-HT1 receptor agonists like TFMPP and mCPP, or mixed 5-HT 1A/1B 
receptor agonists like RU24969 and eltoprazine with selective 5-HT1A receptor 
agonists like 8-OH-DPAT, or in combination with 5-HT1B receptor antagonists, like 
cyanopindolol and propranolol. Stimulation of 5-HT1B receptors has been found to 
be involved in a variety of behaviours. Aggressive behaviour in rodents is reduced 
by so-called serenics, compounds with high affinity for 5-HT1B receptors such as 
eltoprazine, a 5-HT1A/1B receptor agonist (Olivier and Mos, 1992). Furthermore, 5-
HT1B receptors have been implicated in locomotor activity (Geyer, 1996), 
thermoregulation, sexual behaviour, feeding behaviour, and anxiety (see for a 
review Chopin et al., 1994).  
 
 
Psychiatric disorders and 5-HT1B receptors  
 
5-HT and stress 
It is well known that stress affects the serotonergic system (Chaouloff et al., 
1999). For example, the stress-related neuropeptide corticotropin-releasing factor 
(CRF) modulates the neuronal firing activity of the DRN (Lowry et al., 2000, Kirby 
et al., 2000) and several in vivo microdialysis studies have shown that stress 
affects extracellular 5-HT in the hippocampus (Adell et al., 1997, Kirby et al., 
1995, Linthorst et al., 2000). The functional responsiveness of 5-HT1B receptors, 
as measured on 5-HT and acetylcholine release in hippocampal synaptosomes, 
has been shown to be reduced after acute restraint stress, suggesting that 5-HT1B 
receptors desensitize after stress (Bolanos-Jimenez et al., 1995). Learned 
helplessness is a model in which some (but not all) animals that are exposed to 
inescapable foot shock stress, display learned helpless behaviour when tested 24 
hours later in a foot shock avoidance paradigm. The learned helplessness 
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paradigm models some aspects of stress-related disorders including depression 
and post-traumatic stress disorder. Increases in 5-HT1B receptor mRNA levels in 
the DRN have been observed in helpless rats, suggesting increased synthesis of 
5-HT1B autoreceptors (Neumaier et al., 1997). Furthermore, in the cortex of 
helpless rats, increased 5-HT1B receptor binding sites were observed, while 
cortical levels of extracellular 5-HT were decreased, supporting the hypothesis 
that a deficit in 5-HT release is associated with learned helpless behaviour (see 
Moret and Briley, 2000).  
 
5-HT autoreceptors and the action of SSRIs 
SSRIs are widely used in the treatment of depression; however, it takes several 
weeks of chronic administration before a therapeutic effect is achieved. This 
delayed therapeutic onset of SSRIs and other antidepressants can be explained 
by adaptive changes in 5-HT autoreceptors (see for a extensive review Pineyro 
and Blier, 1999). At the beginning of treatment with a SSRI, extracellular 5-HT 
levels are increased. Subsequently, the increased 5-HT levels in the raphe nuclei 
results in inhibition of 5-HT neuronal firing (Sprouse and Aghajanian, 1987), 5-HT 
synthesis (Barton and Hutson, 1999) and release (Adell and Artigas, 1991, Hjorth 
and Auerbach, 1994). After sustained administration of a SSRI, the 5-HT1A 
autoreceptor desensitizes and firing activity is restored in the presence of the 
SSRI (Blier et al., 1998, Hjorth et al., 2000). A limiting role of 5-HT autoreceptors 
in the acute effects of SSRIs is supported by several microdialysis studies (see 
box 2) that have used 5-HT1A receptor antagonists (Invernizzi et al., 1997, Hjorth, 
1993, Trillat et al., 1998) and 5-HT1B receptor antagonists (Rollema et al., 1996, 
Cremers et al., 2000, Gobert et al., 2000). Moreover, administration of SSRIs 
combined with both 5-HT1A and 5-HT1B receptor blockade results in a synergistic 
increase of extracellular 5-HT (Gobert et al., 1997, Dawson and Nguyen, 2000, 
Sharp et al., 1997). Furthermore, following chronic SSRI treatment changes in 5-
HT1B receptors have been demonstrated, suggesting a role of 5-HT1B receptors in 
the mechanism of action of SSRIs (O'Connor and Kruk, 1994, el Mansari et al., 
1995, Newman et al., 2000). That adaptive changes of 5-HT autoreceptors are 
implicated in the delayed therapeutic effect of SSRIs in depression is supported 
by the acceleration of the antidepressant response of SSRIs when combined 
administration with the 5-HT1A autoreceptor antagonist pindolol in patients (see 
box 3).  
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 Box 2. In vivo brain microdialysis 
Microdialysis studies have provided important information on the function of the 
5-HT system, and particularly contributed to the understanding of the in vivo 
effects of antidepressants on extracellular 5-HT (and other neurotransmitters) in 
different brain structures. The in vivo brain microdialysis technique was 
developed in the 1980s, initially to study DA neurotransmission (Zetterstrom et 
al., 1983) and soon followed by studies on extracellular 5-HT (Kalen et al., 
1988). In this technique, a small probe with a permeable membrane is inserted 
in a brain structure of interest while artificial cerebrospinal fluid is perfused 
through the probe. Neurochemicals that passively diffuse across the membrane, 
are collected in the perfusion fluid, and are subsequently measured by means 
of high-pressure liquid chromatography with electrochemical detection (HPLC-
ECD). Studies with tetrodotoxin added or Ca2+ omitted from the perfusion fluid 
indicated that extracellular 5-HT is of neuronal origin. Moreover, autoreceptor 
induced changes in 5-HT output support that the sampled neurotransmitter is 
directly related to neurotransmission. Therefore, it is assumed that extracellular 
5-HT, sampled by means of in vivo microdialysis reflects functional release of 5-
HT (Westerink and Timmerman, 1999). The levels of 5-HT in dialysates are in 
general low (femtomole range), therefore usually samples of 10 to 20 minutes 
are collected to yield 5-HT levels above detection limit. The amount of 5-HT in 
dialysis samples is dependent on the surface (active tip) of the dialysis 
membrane and on the flow rate of the perfusion fluid. In many studies, a SSRI is 
added to the perfusion fluid to increase 5-HT levels. To study 5-HT1B 
autoreceptors, adding a SSRI to the perfusion fluid is not desirable, because 
this increases extracellular 5-HT and subsequently activates 5-HT1B 
autoreceptors. Microdialysis studies have been performed mostly in rat and 
guinea pig, but with the generation of mutant mice, the application of the 
microdialysis technique in mice became of interest. The relative small brain of 
mice restricts the method to larger brain structures like the frontal cortex, 
hippocampus or striatum.  
 
 
Obsessive compulsive disorder 
SSRIs are not only used as antidepressants, but are also effective in the 
treatment of obsessive compulsive disorder (OCD), an anxiety disorder 
(Hollander, 1998, Blier and de Montigny, 1999). In depression it requires several 
weeks before a therapeutic effect of SSRI is obtained, while in OCD patients 
treatment with SSRIs requires higher dosages with an even later therapeutic 
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onset to obtain an anti-obsessional effect. It was hypothesized that this later 
therapeutic onset in OCD (about 8 weeks) is necessary to desensitize terminal 5- 
HT receptors in the orbital frontal cortex (el Mansari et al., 1995). The orbital 
frontal cortex is thought to be involved in OCD, based on changes in brain activity 
(glucose metabolism) of OCD patients demonstrated by means of in vivo imaging 
studies, and moreover, these changes could be restored by chronic treatment with 
SSRIs (Saxena et al., 1999). Pharmacological studies in humans are limited due 
to restricted availability of drugs, but anti-migraine drugs such as sumatriptan and 
zolmitriptan, both 5-HT1B/1D receptor agonists, can be used and have been shown 
to increase plasma growth hormone (Whale et al., 1999). A role of 5-HT1B/1D 
receptors in OCD, was suggested by a study indicating that OCD symptoms were 
worsened in patients following a challenge with sumaptriptan (Dolberg et al., 
1996), but this could not be confirmed by others using sumatriptan or zolmitriptan 
(Ho Pian et al., 1998, Boshuisen and den Boer, 2000). Interestingly, children with 
oppositional defiant disorder (ODD), a disorder associated with aggressive and 
impulsive behaviour, showed an increased response to sumatriptan on growth 
hormone (Snoek et al., 2002). 
 
Variations in the 5-HT1B receptor gene 
The serotonergic system provides interesting candidate genes, including the 5-
HT1B receptor gene, for studies on genetic polymorphism in psychiatric disorders 
(see for a review Veenstra-VanderWeele et al., 2000). Polymorphisms, or 
variations, in the 5-HT1B receptor gene may be important in the development of 
pathophysiology and may be important in determining the response to drugs of 
abuse. At least three polymorphisms (G861C, T-261G and T371G) in the human 
5-HT1B gene are known and in a preliminary family based study the presence of a 
linkage disequilibrium between a 5-HT1B receptor gene polymorphism (G861C) 
and OCD was found (Mundo et al., 2000). In a Finnish population, an association 
between antisocial alcoholism and a 5-HT1B receptor polymorphism (G861C) was 
suggested (Lappalainen et al., 1998), although such an association of 5-HT1B 
receptors to antisocial substance abuse was not found by others (Kranzler et al., 
2002). Also a postmortem study could not identify a relationship between suicide, 
major depression, alcoholism or pathological aggression with 5-HT1B receptor 
binding or the G861C genotype (Huang et al., 1999). Nevertheless, studies on 
genetic polymorphism need examination of large populations, thus future studies 
may reveal or exclude involvement of 5-HT1B receptor gene variations in different 
psychiatric disorders. 
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Box 3. Augmentation strategies for SSRI-treatment 
There is some clinical evidence indicating that co-administration of pindolol, a ß-
adrenoceptor and 5-HT1A receptor antagonist, has an accelerating effect on the 
treatment with SSRIs (Artigas et al., 2001), although larger controlled studies 
could not support this finding (McAskill et al., 1998). It is debated whether the 
effects of pindolol on SSRIs are mediated through blockade of 5-HT1A 
autoreceptors, as a PET study revealed that not more than 40% of 5-HT1A 
autoreceptors are occupied at the pindolol dosages used (Rabiner et al., 2001). 
Moreover, a preclinical study in guinea pigs suggested that the observed effects 
on 5-HT output by pindolol might be due through ß-adrenoceptor blockade 
(Cremers et al., 2001). Furthermore, pindolol has been shown to display partial 
agonistic properties at 5-HT1A receptors (Sprouse et al., 2000, Arborelius et al., 
2000). Although the findings with pindolol seem conflicting, it indicates the 
clinical potential of blockade of 5-HT autoreceptors with more selective ligands 
at the start of treatment with a SSRI may have a beneficial effect in patients with 
major depression. 
 
 
 
5-HT1B receptor knockout mice  
 
Due to a lack a selective receptor antagonists, the generation of constitutive 5-
HT1B receptor knockout mice yielded a new model to study the functional role of 5-
HT1B receptors. By homologous recombination in embryonic stem cells, 
homozygous mutant mice lacking both copies of the gene encoding the 5-HT1B 
receptor were generated (see for details Saudou et al., 1994).  
 
Behavioural phenotype 
Locomotor activity in 5-HT1B receptor knockout mice is normal, but a role of the 5-
HT1B receptors in locomotor activity is supported by the finding that the locomotor 
response to RU24969, a 5-HT1A/1B receptor agonist, is absent in the knockouts 
(Saudou et al., 1994, Ramboz et al., 1996). In a resident intruder paradigm, 5-
HT1B receptor knockout mice are more aggressive relative to wildtype mice, which 
is in line with previous findings that activation of 5-HT1B receptors reduces 
aggressive behaviour in rodents (Saudou et al., 1994, Bouwknecht et al., 2001a). 
5-HT1B knockout mice display increased exploratory behaviour (Malleret et al., 
1999) and response to novelty (Zhuang et al., 1999). Increased impulsivity in 5-
HT1B receptor knockout mice has been suggested (Brunner and Hen, 1997) and is  
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supported by findings that 5-HT1B receptor knockouts show more impulsive 
behaviour in a operant paradigm of decision making and response inhibition (Pattij 
et al., 2002). The altered exploratory behaviour and the observed increased 
aggressive and impulsive behaviour, suggest that 5-HT1B receptor knockout mice 
are more reactive to mild disturbances in their environment. This suggestion is 
further supported by the finding that physiological reactions to mild disturbances 
are increased in these knockouts (Bouwknecht et al., 2000a, 2001a). The 5-HT1B 
receptor knockout mouse has been proposed as a model for substance abuse 
(Scearce-Levie et al., 1999). 5-HT1B receptor knockout mice show an increased 
vulnerability to cocaine and an increased propensity to self-administer this drug 
(Rocha et al., 1998). Increased alcohol consumption is reported in 5-HT1B receptor 
knockout mice (Crabbe et al., 1996), although this finding could not be replicated 
by others (Phillips et al., 1999, Risinger et al., 1999, Bouwknecht et al., 2000b, 
Gorwood et al., 2002).  
 
Serotonergic system of 5-HT1B KO mice 
In the absence of inhibitory 5-HT1B autoreceptors, increases in 5-HT levels may be 
expected. Serotonergic neurons in the DRN of 5-HT1B receptor knockout mice 
displayed normal firing properties and a normal response to 5-HT1A autoreceptor 
activation (Evrard et al., 1999). Electrically evoked release of 5-HT was increased 
in the raphe and hippocampus brain slice of 5-HT1B receptor knockout mice 
(Pineyro et al., 1995b), but a microdialysis study showed that depolarisation 
evoked 5-HT release in the hippocampus and cortex was similar in wildtype and 
knockouts and furthermore, basal 5-HT levels were normal in these brain 
structures (Trillat et al., 1997). In brain tissue of 5-HT1B receptor knockouts 
decreased 5-HT levels were found in some brain areas, such as the spinal cord 
and nucleus accumbens, but not in most other forebrain regions examined, 
suggesting normal biosynthesis of 5-HT in the main serotonergic projection areas 
including the cortex and hippocampus (Ase et al., 2000). These normal properties 
of the 5-HT system may be the result of compensatory changes in 5-HT1B receptor 
knockout mice. Changes in 5-HT transporters have been observed in some brain 
structures, together with increased 5-HT innervation in the amygdalo-hippocampal 
nucleus and the ventral hippocampus of the knockouts, indicating region specific 
adaptive changes in the serotonergic system to compensate for the loss of 5-HT1B 
receptors (Ase et al., 2001).  
After acute administration of the SSRIs paroxetine and fluoxetine, augmented 5-
HT levels were reported in the hippocampus, but not in the striatum of 5-HT1B 
receptor knockout mice (Malagie et al., 2001, Knobelman et al., 2001a), and in the 
frontal cortex an augmented response was only found after a lower dose of 
General introduction | 15 
paroxetine (Malagie et al., 2001). Possibly, upon systemic administration of 
SSRIs, the contribution of terminal 5-HT1B receptors on 5-HT output in the striatum 
and frontal cortex was obliterated by the simultaneous activation of 5-HT 
autoreceptors in the raphe.  
 
 
Aims and outline 
 
The aim of this thesis is to explore the role of 5-HT1B receptors in 5-HT function, 
by comparing the neurochemical effects of different serotonergic drugs on 
extracellular 5-HT and DA levels in wildtype and 5-HT1B receptor knockout mice, 
and in rats using a selective 5-HT1B receptor antagonist.   
In part I of this thesis, in vivo microdialysis studies in wildtype and 5-HT1B receptor 
knockout mice are described. To examine the functional role of the 5-HT1B 
autoreceptors in the regulation of 5-HT release, the effects of 5-HT1B receptors 
stimulation and administration of SSRIs in different brain structures were 
compared in the two genotypes. The SSRI fluvoxamine was locally administered 
into serotonergic projection areas to circumvent activation of 5-HT autoreceptor in 
the raphe nuclei that affect 5-HT output at nerve terminals. The effects of SSRIs, 
systemic paroxetine and local fluvoxamine, on hippocampal 5-HT levels are 
described in chapter 2. The role of 5-HT1B receptors in 5-HT output in the mPFC 
was assessed in chapter 3 by local administration of fluvoxamine and by co-
administration of the selective 5-HT1B receptor antagonist NAS-181. In chapter 4, 
the interaction between 5-HT and DA in the striatum was examined as previous 
studies in rat indicated that stimulation of 5-HT1B receptors increases DA outflow. 
To assess, both the role of 5-HT1B autoreceptors on 5-HT output and the role of 5-
HT1B heteroreceptors on DA output, 5-HT1B receptors were stimulated directly by 
a 5-HT1B receptor agonist and indirectly by enhancing 5-HT levels through local 
administration of a SSRI and a 5-HT releaser.  
In part II, the effect of NAS-181, a new selective rodent 5-HT1B receptor 
antagonist, on extracellular 5-HT was evaluated using microdialysis in rat frontal 
cortex. In chapter 5, the potency of NAS-181 to antagonize the decrease in 5-HT 
induced by a 5-HT1B receptor agonist was compared with two other 5-HT1B 
receptor antagonist, both in the presence and absence of a SSRI. In the study 
presented in chapter 6, tested the hypothesis whether the effect of a 5-HT1B 
receptor antagonist depends on extracellular 5-HT levels by using different 
strategies to increase cortical 5-HT levels combined with administration of NAS-
181. In chapter 7, the main findings are discussed and concluded with future 
directions. 
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CHAPTER 2 
 
 
 
The effects of selective serotonin reuptake 
inhibitors on extracellular 5-HT in the hippo-
campus of 5-HT1B  receptor knockout mice 
 
Lotte de Groote, Berend Olivier, Herman G.M. Westenberg (2002)  
European Journal of Pharmacology 439, 93-100 
 
 
 
 
 
 
 
 
 
 
Abstract 
 
The effects of two selective serotonin reuptake inhibitors (SSRIs) on 5-hydroxy- 
tryptamine (5-HT) in the hippocampus were studied in wildtype and in 5-HT1B 
receptor knockout (KO) mice using in vivo microdialysis. Basal 5-HT levels were 
not different between the two genotypes. The functional absence of 5-HT1B 
receptors was examined in the knockout mice by local infusion of the 5-HT1B 
receptor agonist, CP93129 (1,4-Dihydro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-5H-
pyrrolo[3,2-b]pyridin-5-one) into the hippocampus. CP93129 (1 µM) decreased 5-
HT levels in wildtype mice, but not in 5-HT1B KO mice. Systemic administration of 
the SSRI paroxetine (5 mg/kg i.p.) increased extracellular 5-HT levels.  The 
increase of 5-HT in 5-HT1B KO mice was almost twofold higher than in wildtype 
mice. Systemic administration of SSRIs stimulates both terminal 5-HT1B 
autoreceptors and somatodendritic 5-HT1A autoreceptors. Therefore, another 
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SSRI, fluvoxamine, was applied locally into the hippocampus in order to activate 
only terminal 5-HT1B autoreceptors. Local administration of 0.3 µM fluvoxamine 
resulted in comparable increases in extracellular 5-HT in both genotypes, whereas 
1.0 µM fluvoxamine produced a twofold greater increase in 5-HT levels in 5-HT1B 
KO as compared to wildtype mice. In conclusion, the differences in hippocampal 
5-HT output between wildtype and 5-HT1B KO mice after local or systemic SSRI 
administration show that 5-HT1B autoreceptors play a significant role in the 
inhibition of 5-HT release at serotonergic nerve terminals. In addition, the different 
dose-response to fluvoxamine between the two genotypes also suggest that 5-
HT1B KO mice have possible adaptations of 5-HT transporters in order to 
compensate for the loss of the terminal 5-HT1B autoreceptor. 
 
 
Introduction 
 
Selective serotonin reuptake inhibitors (SSRIs) are widely used in the treatment of 
psychiatric conditions like depression and anxiety disorders. SSRIs exert their 
effects by blocking serotonin (5-HT) reuptake, thereby increasing extracellular 5-
HT levels. Since the onset of clinical efficacy is delayed to 2-4 weeks, it is 
suggested that adaptive processes might be implicated. The release of 5-HT in 
the forebrain is controlled by autoreceptors on serotonergic cell bodies and on 
terminals in projection areas. The terminal 5-HT autoreceptor is of the 5-HT1B 
subtype and stimulation of this receptor results in decreased 5-HT release (Engel 
et al., 1986, Maura et al., 1986, Hoyer and Middlemiss, 1989). In vivo 
microdialysis studies have shown that local infusion of a 5-HT1B receptor agonist 
into the hippocampus results in a decrease of extracellular 5-HT in rat (Hjorth and 
Tao, 1991, Bosker et al., 1995) and mouse (Trillat et al., 1997). Chronic treatment 
with antidepressants alters 5-HT autoreceptors in rats (Haddjeri et al., 1999, Le 
Poul et al., 2000). Terminal 5-HT1B receptors in different brain areas including the 
hippocampus, hypothalamus and frontal cortex have been found to desensitize 
after sustained administration of SSRIs (Blier et al., 1984, Moret and Briley, 1990, 
O'Connor and Kruk, 1994, el Mansari et al., 1995, Newman et al., 2000). Several 
studies on the role of autoreceptors in the mechanism of action of SSRIs, have 
used selective 5-HT1A and non-selective 5-HT1B/1D receptor antagonists in 
combination with SSRIs. The combination of a SSRI with a 5-HT1A and 5-HT1B 
receptor antagonists synergistically increases 5-HT release in rat frontal cortex 
(Gobert et al., 1997, Sharp et al., 1997, Dawson and Nguyen, 2000), guinea pig 
frontal cortex, hippocampus (Roberts et al., 1996) and hypothalamus (Rollema et 
al., 1996). Due to a lack of selective 5-HT1B receptor antagonists, there is 
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relatively little data on the role of the terminal 5-HT1B autoreceptor in controlling 5-
HT release. The selective 5-HT1B receptor antagonist, SB-224289, potentiated the 
effect of fluoxetine in rat frontal cortex (Gobert et al., 2000) and produced an 
increase in extracellular 5-HT in the hippocampus, but not in the frontal cortex of 
guinea pigs (Roberts et al., 1998). 5-HT1B receptors are located in serotonergic 
projections to forebrain regions as terminal autoreceptors and as heteroreceptors. 
Several studies indicate that 5-HT1B receptors present in the dorsal raphe nucleus 
(DRN) are also involved in the release of 5-HT (Starkey and Skingle, 1994, 
Pineyro et al., 1995a, Moret and Briley, 1997, Davidson and Stamford, 1995). 
Thus, blockade of 5-HT1B/1D receptors in the raphe nuclei after systemic 
administration of 5-HT1B/1D receptor antagonists may also contribute to the effects 
on 5-HT levels in output areas.  
The development of 5-HT1B receptor knockout (KO) mice has generated a model 
to study the importance of the 5-HT1B receptor (Saudou et al., 1994) and allows 
the investigation of SSRI actions in the absence of 5-HT1B receptors. Recent 
studies have found increased 5-HT levels in hippocampus and frontal cortex after 
systemic SSRI administration in mice lacking 5HT1B receptors (Malagie et al., 
2001, Knobelman et al., 2001b). 
In the present study we report on the effects of SSRIs on 5-HT release in the 
hippocampus of wild type and 5-HT1B KO mice following systemic and local 
administration. In mice lacking the 5-HT1B receptor, augmented 5-HT responses 
are expected following SSRI administration due to the absence of inhibitory 
terminal 5-HT1B autoreceptors. Since, systemic administration of SSRIs also 
activates 5-HT autoreceptors in the raphe nuclei, effects of local administration of 
the SSRI fluvoxamine were studied to assess the role of the terminal 5-HT1B 
autoreceptor.  
 
 
Material & Methods 
 
Animals 
In this study, male wildtype and 5-HT1B knockout mice with a 129/SV genetic 
background were tested. The mice were group-housed, eight per cage and kept 
on a 12-hour light-dark cycle (6 a.m. on, 6 p.m. off) at constant room temperature 
(22 ± 2°C) with freely available food and water. For the experiments, bodyweights 
of the mice were between 25 and 30 grams at an age between 12 and 16 weeks. 
The two genotypes differ in bodyweight, the 5-HT1B KO mice being slightly heavier 
as compared to the wildtype mice (Bouwknecht et al., 2001b). Wildtype and 5-
HT1B knockout mice were bred in separate homozygous lines at the animal 
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facilities, GDL, Utrecht, The Netherlands. The original wildtype and 5-HT1B 
knockout mice were obtained from Dr. René Hen, Columbia University, New York, 
USA. See for details on the generation of the 5-HT1B KO mice the original 
publication by Saudou et al (1994). The ethical committee for animal research of 
the University Medical Center Utrecht, The Netherlands, approved the study. 
 
Surgery 
Mice were anaesthesized with chloralhydrate (400 mg/kg, i.p.) and lidocaine (2%) 
was applied on the skull. For surgery, the mice were placed in a stereotaxic frame 
using a mouse adaptor (Stoelting, Germany) with modified earbars. The mice 
were on a heating pad during surgery. A small hole was drilled in the skull for the 
implantation of the probe and two small holes for anchor screws. A self-
constructed microdialysis probe with an AN filtral 69 membrane, outer diameter 
310 µM (Hospal, Uden, The Netherlands), was placed in the right hippocampus. 
The coordinates were: AP -2.8 mm from bregma, ML -3.5 mm, DV -4.0 mm from 
dura, according to the stereotaxic atlas of the mouse brain (Franklin and Paxinos, 
1997). The exposed membrane tip length was 2 mm. The probe was secured in 
place with dental cement and two anchor screws in the skull. After surgery, mice 
were injected with saline (0.5 ml i.p.) to prevent dehydratation and the mice were 
housed separately. 
 
Microdialysis 
Microdialysis experiments started the day after surgery. Mice were tested on two 
subsequent days to reduce the number of animals. The treatment groups were 
randomized over the two days. Mice were in their homecage during the 
experiments. The animals were connected to a high precision pump (Harvard 
PHD2000, Harvard Scientific, USA) using mouse swivels (Type 375/25, Instech 
Laboratories, Inc, USA) and PEEK-tubing (ID0.005”, OD0.020”) to allow free 
movements of the mice. Ringer solution (147 mM NaCl, 2.3 mM KCl, 
 
2.3 mM 
CaCl2, 1.0 mM MgCl2) was perfused through the microdialysis probe with a flow of 
1.13 µl/min. The experiments were performed during the light phase and started 
after three hours equilibration. Samples were collected every 20 minutes in vials 
containing 7.5 µl acetic acid, using fraction collectors (type 142, CMA, Sweden). 
Samples were stored at –80°C until High Performance Liquid Chromatography 
(HPLC) analysis. At the end of the experiment the mice were decapitated, the 
brains were removed and fixed in 4% formaldehyde. The brains were cut in 50 µm 
slices on a vibratome to verify the position of the probe. In case of improper probe 
placement, data was excluded.  
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Drugs 
Paroxetine (donated by GSK, Harlow, UK) was dissolved in sterile 0.9 % saline on 
the day of the experiment.  Fluvoxamine (donated by Solvay Pharmaceuticals, 
Weesp, The Netherlands) and CP93129 dihydrochloride (1,4-Dihydro-3-(1,2,3,6-
tetrahydro-4-pyridinyl)-5H-pyrrolo[3,2-b]pyridin-5-one, obtained from Tocris, UK) 
were dissolved in Ringer solution.  
 
HPLC-ECD analysis 
5-HT was analyzed by HPLC with electrochemical detection. Samples (25 µl) 
were injected onto a LUNA 3 µm RP18 column (100x2 mm, Phenomenex, Bester, 
The Netherlands) using a Triathlon autosampler and a Gynkotek P580 pump 
(Separations, The Netherlands). Separation was performed at 40ºC. The 
electrochemical detector (Intro, ANTEC Leyden, The Netherlands) was set at a 
potential of 600 mV against an Ag/AgCl reference electrode. The signal was 
analyzed using Gynkotek software. The mobile phase consisted of 5 g/l 
(NH4)2SO4, 150 mg/l heptane sulphonic acid sodium salt, 0.5 g/l EDTA, 5% 
methanol, 30 µl/l triethylamine, 30 µl/l acetic acid, pH 4.6. Flow rate was 0.3 
ml/min. The detection limit for 5-HT was 0.5 fmol/25 µl sample (signal to noise 
ratio 2). 
 
Data analysis and statistics 
Values for the first four consecutive samples were averaged to calculate the basal 
levels of extracellular 5-HT. Student’s t-tests were used to compare basal 5-HT 
values between the two genotypes. In the figures, all values are expressed as 
percentages of basal levels ± SEM. The data were statistically analyzed with 
SPSS (Version 8.0). Effects of 5-HT response to SSRI treatment were analyzed 
by multivariate analysis of variance (ANOVA) with time as ‘within’ and dose and 
genotype as ‘between’ factors. When appropriate, data were broken down and 
effects of drug dosages or genotype were analyzed by pairwise comparison.  For 
the treatment period, the area under the curve (AUC) was calculated. AUC values 
were analyzed with ANOVA and post hoc analyses when appropriate. The 
significance level for all analyses was set at 5%. In the figures the point of 
injection or start of the local infusion (timepoint zero) is corrected for the lagtime of 
the microdialysis system. 
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Results 
 
Basal 5-HT levels  
Basal levels of extracellular 5-HT in the hippocampus were not different between 
the two genotypes (ANOVA; F(1,68)=2.0, p=0.17, NS). The mean basal levels 
were 5.66 ± 0.47 fmol/sample for wildtype (n=34) and 6.63 ± 0.54 fmol/sample for 
5-HT1B KO mice (n=35).  
 
Effects of the 5-HT1B receptor agonist CP93129 
The 5-HT1B receptor agonist, CP93129 (1 µM), was infused by reversed 
microdialysis for a period of 60 minutes (Fig. 1). ANOVA revealed an effect of 
dose by genotype (F(1,26)=6.8, p<0.05). In wildtype mice, local administration of 1 
µM CP93129 significantly decreased extracellular 5-HT to 58 ± 11% from baseline 
levels. Local infusion of CP93129 had no effect in 5-HT1B KO mice, demonstrating 
the functional absence of 5-HT1B receptors in the knockout mice. 
 
Effects of systemic administration of paroxetine 
Acute administration of paroxetine (5 mg/kg, i.p.) increased extracellular 5-HT in 
the hippocampus of wildtype and 5-HT1B KO mice (Fig. 2). ANOVA revealed 
significant effects of time (F(8,186)=9.7, p<0.001), dose (F(1,21)=20.9, p<0.001) 
and of genotype (F(1,21)=7.8, p<0.05). wildtype mice (F(1,11)=21.9, p<0.01) and 
in 5-HT1B KO mice (F(1,10)=8.7, p<0.05). Contrast analyses revealed a genotype 
effect for paroxetine treatment (F(1,11)=9.0, p<0.05). The paroxetine-induced  
Fig 1. Local administration of the 5-
HT1B receptor agonist CP93129 into
the hippocampus. Mean percent
change in 5-HT from basal levels is
expressed as the AUC ± S.E.M. for
a 120 min period. CP93129 (1 µM)
was infused for 60 minutes.
Symbols: ∗ indicates a significant
drug effect (p<0.05) and ‡ indicates
a significant genotype effect
(P<0.05). For each group n=6-8
mice.  vehicle CP93129
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Fig 2. Systemic injection of paroxetine. Data are expressed as mean percent change in
5-HT from basal levels ± S.E.M.. Saline (â) or paroxetine (5mg/kg, i.p.) (ê) was
injected at timepoint zero in wildtype mice (A) or 5-HT1B knockout mice (B). (C) Mean
percent change in 5-HT from basal levels is expressed as the AUC ± S.E.M. for the
treatment period after i.p. injection of saline or paroxetine (5 mg/kg) injection. Symbols:
∗ indicates a significant drug effect P <0.05) and ‡ indicates a significant genotype effect
(P<0.05). For each group n=6-8 mice. 
-80 -40 0 40 80 120 160
time (min)
100
400
700
1000
1300
1600
%
 c
ha
ng
e 
5-
H
T
wildtype miceA
-80 -40 0 40 80 120 160
time (min)
100
400
700
1000
1300
1600
%
 c
ha
ng
e 
5-
H
T
5-HT1B KO miceB
saline paroxetine
0
200
400
600
800
1000
1200
1400
1600
%
 c
ha
ng
e 
5-
H
T
wildtype
5-HT1B KO
C
*
*‡
24  | CHAPTER 2 
increase in extracellular 5-HT was almost twofold higher in 5-HT1B KO mice as 
compared to the wildtype mice. Taking the AUC as outcome variable similar 
results were obtained (Fig. 2C). 
 
Effects of local administration of fluvoxamine 
The local administration of fluvoxamine (0.3 and 1.0 µM) induced an increase in 
extracellular 5-HT in both genotypes (Fig. 3). ANOVA revealed an effect of time 
(F(12,408)=10.6, p<0.001), of dose (F(2,34)=57.8, p<0.001) and of dose by 
genotype (F(2,34)=10.4, p<0.001). In wildtype mice, administration of 0.3 and 1.0 
µM fluvoxamine induced a significant increase in 5-HT as compared to vehicle 
(F(2,17)=39.0, p<0.001), but no difference between the two fluvoxamine dosages. 
In 5-HT1B KO mice, both dosages of fluvoxamine increased 5-HT levels as 
compared to vehicle (F(2,17)=29.6, p<0.001), the difference being greater with the 
highest dosage. Statistical analyses revealed a dose-dependent effect 
(F(1,11)=14.6, p<0.05). When data were broken down on dosage, a significant 
difference was found for the highest dosage of fluvoxamine between the 
genotypes (F(1,12)=9.1, p<0.05). The highest dosage of fluvoxamine induced an 
almost twofold greater increase in extracellular 5-HT in the knockout as compared 
to the wildtype mice. No differences in 5-HT response were found between the 
genotypes for the lower dosage of fluvoxamine or vehicle. Taking the AUC as 
outcome variable, similar results were obtained. The highest dosage of 
fluvoxamine (1.0 µM) induced in an almost twofold increase in 5-HT in the 
knockouts as compared to the wildtype mice (Fig. 3C).  
 
 
Discussion 
 
The main finding of the present study is that extracellular levels of 5-HT are 
regulated differently in mice lacking the 5-HT1B receptors as compared to wildtype 
mice. Basal extracellular 5-HT levels in 5-HT1B KO and wildtype mice were similar, 
but blockade of 5-HT reuptake sites by systemic paroxetine administration 
resulted in a greater increase in hippocampal 5-HT in the 5-HT1B KO than in 
wildtype mice. Inhibition of the uptake sites in the hippocampus by local 
administration of fluvoxamine resulted also in augmented 5-HT levels in the 5-
HT1B KO mice, but the effect appeared to be dose-related in that it was only 
apparent at the higher SSRI concentration. In addition, local administration of the 
5-HT1B receptor agonist CP93129 into the hippocampus decreased absence of 
the 5-HT1B autoreceptor in the latter strain.  
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Fig 3. Local administration of fluvoxamine into the hippocampus. Data are
expressed as mean percent change in 5-HT from basal levels ± S.E.M.. Ringer
solution (â), 0.3 µM (ê) or 1.0 µM fluvoxamine (ë) was infused for 240 minutes
starting at timepoint zero in wildtype mice (A) or 5-HT1B knockout mice (B). (C)
Mean percent change in 5-HT from is expressed basal levels as the AUC ±
S.E.M. after infusion of Ringer solution (0 µM), 0.3 µM or 1.0 µM fluvoxamine.
Symbols: ∗ indicates a significant drug effect (P<0.05) and ‡ indicates a
significant genotype effect (P<0.05). For each group n=6-8 mice. 
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These data confirm and extend previous findings using systemic administration of 
SSRIs, indicating that 5-HT1B autoreceptor stimulation limit the effects of acute 
SSRI administration (Malagie et al., 2001, Knobelman et al., 2001b). A 
confounding factor of studies using systemic administration of SSRIs is that an 
effect of somatodendritic 5-HT1A autoreceptors on 5-HT output cannot be 
excluded. There is circumstantial evidence that stimulation of 5-HT1B receptors in 
the raphe nuclei may affect 5-HT levels in projection areas (Pineyro and Blier, 
1996, Davidson and Stamford, 1995). Studies with mixed 5-HT1B/1D receptor 
antagonists have revealed differences between the dorsal raphe and medial raphe 
nucleus innervated brain areas (Roberts et al., 1997, Roberts et al., 1998). The 
hippocampus receives innervation from both the dorsal raphe and medial raphe 
nucleus, although there is a preferential input from the medial raphe nucleus to 
the dorsal part of the hippocampus (Steinbusch, 1981, Mokler et al., 1998). 
Moreover, systemic administration of SSRIs may also affect other 5-HT 
modulating receptors in the raphe nuclei, such as the 5-HT1A autoreceptor and the 
5-HT1D receptor. To exclude these effects, we applied the SSRI fluvoxamine and 
the 5-HT1B receptor agonist, CP93129, locally into the hippocampus by reversed 
microdialysis. Although the microdialysis probe was placed mainly in the ventral 
part of the hippocampus, we refer to the hippocampus rather than to the ventral 
hippocampus, due to the relative small size of the mouse brain. We used 
fluvoxamine, rather than paroxetine, because the former SSRI was found to have 
better properties to cross the dialysis membrane used in this study. After local 
administration of fluvoxamine 5-HT levels were stable after one hour of infusion, 
whereas after local infusion of paroxetine (1 µM) 5-HT levels increased slowly and 
were not stable after three hours of infusion (data not shown). Our results confirm 
the view that release of 5-HT in the hippocampus is regulated by terminal 5-HT1B 
autoreceptors. The data are also in line with studies in other species using 5-HT1B 
receptor antagonists. Thus, GR127935, a mixed 5-HT1B/1D receptor antagonist, 
potentiated the effects of SSRIs in rat frontal cortex, presumably by blocking 
terminal 5-HT1B autoreceptors, after systemic (Gobert et al., 1997, Roberts et al., 
1997 or local administration (Hertel et al., 1999). SB224289, a more selective 5-
HT1B receptor antagonist, also augmented the SSRI-induced increase of 
extracellular 5-HT levels in rat frontal cortex, and guinea pig frontal cortex and 
hippocampus (Gobert and Millan, 1999, Roberts et al., 1999). Finally, local 
administration of a new selective 5-HT1B receptor antagonist, NAS-181, in the 
presence of a SSRI, resulted in increased extracellular 5-HT levels in rat 
hippocampus and prefrontal cortex (Hjorth et al., 2000). Taken together, these 
findings support the notion that terminal 5-HT1B autoreceptors negatively regulate 
5-HT release and thereby restrain the effects of acute SSRI administration. Thus, 
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increased 5-HT levels were expected in mice lacking 5-HT1B receptors. In line with 
previous studies, we found that basal 5-HT levels in 5-HT1B KO mice were not 
different from those in the wildtype mice (Malagie et al., 2001, Knobelman et al., 
2001a). This would suggest that either 5-HT1B receptors do not display 
endogenous activity under basal conditions or that compensatory changes have 
taken place during neurodevelopment. Interestingly, we found that two 
concentrations of fluvoxamine (0.3 and 1.0 µM) resulted in similar increases in 
extracellular 5-HT in the wildtype mice, suggesting that a maximum blockade of 5-
HT reuptake was already achieved after the lower concentration of fluvoxamine. In 
5-HT1B KO mice, on the other hand, the increase in extracellular 5-HT was not 
different from the wildtypes at the lower concentration of fluvoxamine, but 
augmented at the higher concentration, indicating a different dose-response 
relationship. A likely explanation could be an adaptation of the 5-HT transporter in 
the 5-HT1B KO mice during development, resulting in a different functional 
capacity. A higher uptake capacity could compensate for the lack of terminal 5-HT 
autoinhibition and may account for the normal basal 5-HT levels in the 5-HT1B KO 
mice as well as the higher concentration of the SRRI necessary to completely 
block the uptake of 5-HT. Developmental alterations have been previously 
described for the 5-HT transporter KO mice. These 5-HT transporter KO mice 
have upregulated 5-HT1A and 5-HT1B receptors in some brain areas to 
compensate for the lack of 5-HT transporters (Fabre et al., 2000). There is 
evidence for adaptation of the 5-HT1A receptors based on the finding that 5-HT1B 
KO mice show a reduced 5-HT response in the hippocampus after systemic 
injection of a 5-HT1A receptor agonist (Knobelman et al., 2001a). The authors 
propose based on this finding that 5-HT1B KO mice have desensitized 5-HT1A 
receptors in the MRN to compensate for the loss terminal 5-HT1B autoreceptors. 
These finding are not supported by other studies, since densities of 5-HT1A 
receptors (Malleret et al., 1999, Evrard et al., 1999) and raphe neuronal firing after 
stimulation of 5-HT1A receptors are normal in  5-HT1B KO mice (Evrard et al., 
1999). Furthermore, postsynaptic 5-HT1A receptor function as measured by 
corticosterone release was normal in 5-HT1B KO Bouwknecht et al., 2001c. In the 
present study, SSRIs were administered locally into the hippocampus and 
therefore it is unlikely that somatodendritic 5-HT autoreceptor changes account for 
the present findings. Recently, regional changes in 5-HT transporters have been 
reported for 5-HT1B KO mice. Binding densities of 5-HT transporters were 
increased in the ventral hippocampus and amygdalo-hippocampal nucleus of 5-
HT1B KO mice (Ase et al., 2001). A higher density of 5-HT reuptake sites has also 
been demonstrated for the raphe nuclei of 5-HT1B KO mice (Evrard et al., 1999). 
In support of the explanation that 5-HT1B KO mice have changes in 5-HT 
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transporters, an interesting interaction between the 5-HT transporter and the 5-
HT1B receptor has been reported. The clearance of 5-HT by the 5-HT transporter 
was prolonged after blockade of 5-HT1B receptors in the hippocampus (Daws et 
al., 2000). This finding suggests plasticity between the 5-HT transporter and the 5-
HT1B autoreceptor. Taken together, these findings support compensatory changes 
of 5-HT transporters in mice lacking 5-HT1B receptors.  
In conclusion, the differences in hippocampal 5-HT output between wildtype and 
5-HT1B KO mice after local or systemic SSRI administration show that 5-HT1B 
autoreceptors play a significant role in the inhibition of 5-HT release at 
serotonergic nerve terminals. In addition, the results also suggest that 5-HT1B KO 
mice have possible adaptations of 5-HT transporters in order to compensate for 
the loss of the terminal 5-HT1B autoreceptor. 
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Abstract 
 
Rationale: 5-HT autoreceptors regulate extracellular 5-HT levels and have been 
suggested to limit the effects of acute treatment with selective serotonin reuptake 
inhibitors (SSRI). Objectives: The role of terminal 5-HT1B autoreceptors was 
assessed by comparing the effects of a SSRI on extracellular 5-HT in wildtype and 
5-HT1B receptor knockout mice, and by using a 5-HT1B receptor antagonist. Since 
systemic SSRI-administration also activates somatodendritic 5-HT1A 
autoreceptors, a SSRI was administered locally to study the role of terminal 5-
HT1B autoreceptors. Methods: In vivo microdialysis in wildtype and 5-HT1B 
receptor knockout (KO) mice was used to study the effects of the 5-HT1B receptor 
agonist CP93129 (1 µM), the SSRI fluvoxamine (0.3 and 1.0 µM) and the 5-HT1B 
receptor antagonist NAS-181 (1 µM) on extracellular 5-HT in the medial prefrontal 
cortex (PFC). Results: The 5-HT increase induced by local SSRI-administration 
was augmented in 5-HT1B KO mice as compared to wildtype mice and was 
augmented by simultaneous administration of a 5-HT1B receptor antagonist in the 
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latter genotype. Basal 5-HT levels did not differ between the two genotypes. 
Activation of 5-HT1B receptors by CP93129 decreased extracellular 5-HT, 
whereas, 5-HT levels in wildtype mice were not affected by the 5-HT1B receptor 
antagonist NAS-181. In 5-HT1B KO mice, NAS-181 did not affect extracellular 5-
HT and did not further increase the effect of fluvoxamine, showing that NAS-181 is 
a selective 5-HT1B receptor antagonist. The greater increase in 5-HT levels 
following combined administration of a SSRI with NAS-181 in wildtype mice, as 
compared to 5-HT1B KO mice, suggests possible adaptive changes in the 
knockout mice. Conclusions: The present study shows that terminal 5-HT1B 
autoreceptors play a significant role in the regulation of 5-HT release in the PFC. 
 
 
Introduction 
 
The prefrontal cortex (PFC) plays a key role in cognitive and emotional processes, 
functions affected in depression, anxiety and other psychiatric disorders. An 
important target in the treatment of psychiatric disorders is the 5-HT transporter. 
Selective serotonin reuptake inhibitors (SSRIs) are widely used in the treatment of 
depression and anxiety disorders. SSRIs exert their effects by blocking 5-HT 
reuptake, thereby increasing extracellular 5-HT levels. Under normal conditions, 
5-HT is rapidly cleared from the synaptic cleft by 5-HT transporters. The release of 
5-HT is controlled by 5-HT1A autoreceptors on serotonergic cell bodies and by 5-
HT1B autoreceptors on nerve terminals. Thus, activation of terminal 5-HT1B 
autoreceptors attenuates 5-HT release (Engel et al., 1986, Maura et al., 1986, 
Hoyer and Middlemiss, 1989). In vivo microdialysis studies in rats and mice have 
shown that local administration of a 5-HT1B receptor agonist into serotonergic 
projection areas decreases extracellular 5-HT (Hjorth and Tao, 1991, Bosker et 
al., 1995, Trillat et al., 1997, Hertel et al., 1999). Since the onset of clinical efficacy 
of SSRIs is achieved only after several weeks of treatment, it is suggested that 
adaptive processes are implicated. Chronic treatment with antidepressants alters 
5-HT autoreceptors in rats (Haddjeri et al., 1998, Le Poul et al., 2000). Terminal 5-
HT1B receptors in different brain areas including the PFC have been found to 
desensitize after sustained administration of SSRIs (Blier et al., 1984, Moret and 
Briley, 1990, O'Connor and Kruk, 1994, el Mansari et al., 1995, Newman et al., 
2000). To accelerate the efficacy of SSRIs, augmentation strategies with 5-HT 
autoreceptor antagonists have been suggested (Artigas, 1993, Hjorth, 1993). 
Several studies have shown that concurrent administration of SSRIs with 5-HT1A 
or 5-HT1B antagonists results in augmented 5-HT levels in different forebrain areas 
(Hjorth, 1993, Sharp et al., 1997, Gobert et al., 1997, Roberts et al., 1999, Gobert 
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et al., 2000, Cremers et al., 2000). After systemic SSRI administration, the output 
of 5-HT is affected by somatodendritic 5-HT1A and terminal 5-HT1B autoreceptors. 
There is evidence to suggest that 5-HT1B/1D receptors located in the dorsal raphe 
nucleus are also involved in the release of 5-HT in projection areas  (Starkey and 
Skingle, 1994, Pineyro and Blier, 1996, Pineyro et al., 1995b, Davidson and 
Stamford, 2000). Research on the role of terminal 5-HT1B receptors has been 
impeded by the lack of selective 5-HT1B receptor antagonists. NAS-181 is a new 
selective 5-HT1B receptor antagonist that has shown to enhance 5-HT metabolism 
and synthesis in rat brain (Berg et al., 1998, Stenfors et al., 2000). The 
development of 5-HT1B receptor knockout (KO) mice has generated another 
strategy to study the role of the 5-HT1B receptor (Saudou et al., 1994). Recent 
microdialysis studies in 5-HT1B receptor KO mice have shown increased 5-HT 
levels in the hippocampus or the PFC after systemic SSRI administration of this 
genotype as compared to wildtype mice (Malagie et al., 2001, Knobelman et al., 
2001b, de Groote et al., 2002a).  
In the present study, we report on the local effects of the SSRI fluvoxamine on 
extracellular 5-HT in the PFC of mice. Since systemic administration of SSRIs 
also activates 5-HT autoreceptors in the raphe nuclei, the effects of local 
fluvoxamine administration were studied to assess the role of the terminal 5-HT1B 
receptor. The release limiting effects of 5-HT1B autoreceptors on SSRI-induced 5-
HT increases were studied in wildtype mice by blocking the 5-HT1B receptor and in 
mice lacking 5-HT1B receptors. 
 
 
Material and Methods 
 
Animals 
In this study, male wildtype and 5-HT1B knockout mice on a 129/SV genetic 
background were tested (Saudou et al. 1994). The mice were kept eight per cage 
on a 12-hour light-dark cycle (6 a.m. on, 6 p.m. off) at constant room temperature 
(22 ± 2°C) and controlled humidity. The mice had free access to food and water. 
During the experiments, the mice were between 25-30 grams at an age between 
12-16 weeks. The mice were bred in separate homozygous lines in the animal 
facilities, GDL, Utrecht, The Netherlands. The original wildtype and knockout mice 
were obtained from Dr. René Hen, Columbia University, New York, USA. The 
ethical committee for animal research of the University Medical Center Utrecht, 
The Netherlands, approved the study. 
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Surgery 
Microdialysis probes were implanted in the medial PFC under chloralhydrate 
anaesthesia (400 mg/kg, i.p.) and lidocaine (2%) applied on the skull. For surgery, 
the mice were placed in a stereotaxic frame using a mouse adaptor (Stoelting, 
Germany) with modified earbars. During surgery mice were kept warm on a 
heating pad. A concentric self-constructed microdialysis probe with an AN filtral 69 
membrane, outer diameter 310 µM (Hospal, Uden, The Netherlands), was placed 
in the medial PFC. The coordinates were: AP + 1.95 mm from bregma, ML – 0.7 
mm at an angle of 8º, DV – 3.3 mm from the dura, according to the stereotaxic 
atlas of the mouse brain Franklin and Paxinos, 1997. The active dialysis surface 
length of the membrane was 2 mm. The probe was secured in place with dental 
cement and two anchor screws in the skull. After surgery mice were injected with 
saline (0.5 ml i.p.) to prevent dehydration and the mice were housed separately. 
 
Microdialysis 
Microdialysis experiments started 16-20 hours after surgery. Ringer solution (147 
mM NaCl, 2.3 mM KCl, 
 
2.3 mM CaCl2, 1.0 mM MgCl2) was perfused through the 
microdialysis probe with a flow of 1.13 µl/min using a high precision pump 
(Harvard PHD2000, Harvard Scientific, USA). Mouse swivels (Type 375/25, 
Instech Laboratories, Inc, USA) connected to PEEK-tubing (ID 0.005”, OD 0.020”) 
were used to allow unrestrained movements of the mice. The total dead volume of 
the dialysis system was 45 µl. After the start of the dialysis perfusion mice were 
left undisturbed for three hours. Experiments took place in the light period and the 
mice were in their homecage. Samples were collected every 20 minutes in vials 
containing 7.5 µl acetic acid and stored at –80°C until HPLC analysis. At the end 
of the experiment the mice were killed by cervical dislocation, the brains were 
removed and fixed in 4% formaldehyde solution. To verify the position of the 
probe the brains were cut in 50 µm slices on a vibratome. In case of improper 
probe placement, data was excluded. In total, four mice had had to be excluded 
from the analysis. 
 
Drugs 
The following drugs were used; CP93129 dihydrochloride (1,4-Dihydro-3-(1,2,3,6-
tetrahydro-4-pyridinyl)-5H-pyrrolo[3,2-b]pyridin-5-one, obtained from Tocris, UK), 
fluvoxamine maleate (donated by Solvay Pharmaceuticals, The Netherlands) and 
NAS-181 ((R)-(+)-2-[[[3-(Morpholinomethyl)-2H-chromen-8-yl]oxy]methyl] morpho-
line methane sulfonate), kindly donated by Dr. C. Stenfors (Astra Zeneca, 
Sweden). All drugs were dissolved in distilled water and further diluted in Ringer 
solution on the day of the experiment.  
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HPLC-ECD analysis 
5-HT was analyzed by HPLC with electrochemical detection. Samples were 
injected onto an Inertsil ODS-3 column (3 µM, 2.1x100mm, Aurora Borealis,The 
Netherlands) using a Gilson pump and autosampler (Separations, The 
Netherlands). Separation was performed at 40ºC with the electrochemical detector 
(Intro, ANTEC Leyden, The Netherlands) set at a potential of 600 mV against an 
Ag/AgCl reference electrode. The signal was analyzed using Gynkotek software. 
The mobile phase consisted of 5 g/l (NH4)2SO4, 150 mg/l heptane sulphonic acid 
sodium salt, 0.5 g/l EDTA, 5% methanol, 30 µl/l triethylamine, 30 µl/l acetic acid, 
pH 4.6. Flow rate was 0.3 ml/min. The detection limit for 5-HT was 0.5 fmol/25 µl 
sample (signal-to-noise ratio 2). 
 
Data analysis and statistics 
Values for the first four consecutive samples were averaged to calculate the basal 
levels of extracellular 5-HT. Student’s t-tests were used to compare basal 5-HT 
values between the two genotypes. In the figures, all 5-HT values are expressed 
as percentages of basal levels ± SEM. Effects of 5-HT response to drug treatment 
were analyzed by multivariate analysis of variance (ANOVA) with time as ‘within’ 
and dose and genotype as ‘between’ factors. To test the effects of fluvoxamine 
dosages, area under the curve (AUC) values were calculated for the infusion 
period of vehicle (Ringer solution) and the two dosages of fluvoxamine. AUC 
values were analyzed with ANOVA with dose as ‘within’ and genotype as 
‘between’ subject factors. When appropriate, data were broken down on dose or 
genotype and comparisons were made by simple contrasts. The significance level 
for all analyses was set at 5%. In the figures the start of local infusion (time point 
zero) of drugs is corrected for the lag-time of the microdialysis system. 
 
 
Results 
 
Basal 5-HT levels  
Basal levels of extracellular 5-HT in the PFC of the two genotypes were not 
different (F(1,66)= 0.73, NS). The mean basal levels were 5.3 ± 0.32 fmol/25µl for 
wildtype (n = 36) and 5.1 ± 0.46 fmol/25µl for 5-HT1B KO mice (n = 31).  
 
Local administration of the 5-HT1B receptor agonist CP93129 
The selective 5-HT1B receptor agonist CP93129 (1 µM) was administered by 
reversed microdialysis for 60 minutes. Extracellular 5-HT levels were reduced 
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after CP93129 in wildtype mice, but not in 5-HT1B KO mice as shown in Fig 1. In 
wildtype mice CP93129 reduced extracellular 5-HT to 58 ± 7% as compared to 
vehicle (Ringer solution)  (F(1,13)=15.3, p < 0.01).  
 
Local administration of fluvoxamine 
Local administration of the SSRI fluvoxamine increased extracellular 5-HT as 
shown in Fig. 2. The two dosages of fluvoxamine were administered cumulative 
by reversed microdialysis. After four baseline samples, 0.3 µM fluvoxamine was 
administered for 120 minutes, followed by 1.0 µM fluvoxamine for another 120 
minutes. Multivariate ANOVA indicated a time effect (F(14,336)=26.9, p <0.001), a 
time x treatment interaction (F(14,336)=26.4, p < 0.001), a treatment effect 
(F(1,24)=180.9, p < 0.001), and a genotype effect (F(1,24)=31.8, p < 0.001). In 
wildtype mice, the maximum 5-HT increase was 239 ± 49 % and 352 ± 57 % 
following 0.3 µM or 1.0 µM fluvoxamine, respectively.  In 5-HT1B KO mice, the 
maximum 5-HT increase was 347± 53 % and 710 ± 40 % following 0.3 µM or 1.0 
µM fluvoxamine, respectively. The AUC values in Fig. 2B show the effects of the 
two concentrations of fluvoxamine on 5-HT levels. ANOVA indicated an effect of 
dose for fluvoxamine in wildtype (F(2,12)=21.6, p < 0.001 ) and in 5-HT1B KO mice 
(F(2,14)=171.6, p < 0.001). In both genotypes, fluvoxamine dose-dependently 
increased extracellular 5-HT. The augmentation of 5-HT levels by fluvoxamine 
was significantly greater in the 5-HT1B KO mice than in wildtype mice 
(F(1,13)=22.9, p < 0.001) for both concentrations of fluvoxamine. 
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Fig 1. Local administration of the 5-
HT1B receptor agonist CP93129 into
the PFC. Data are expressed as the
mean percent of basal 5-HT levels ±
SEM. In wildtype (+/+) and 5-HT1B
KO mice (-/-), 1 µM CP93129 was
administered for 60 minutes as
indicated by the bar. For vehicle
groups n=7-9 and for CP93129
groups n=5-6 mice. 
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Fig 2. Local administration of fluvoxamine into the PFC. Data is expressed as mean
percent of basal 5-HT levels ± SEM. A) Time course of the effects of fluvoxamine on
extracellular 5-HT in wildtype (+/+) and 5-HT1B KO mice (-/-). At time point zero
fluvoxamine was administered in two cumulative dosages, first 0.3 µM followed by 1.0
µM as indicated by the striped and black bar, respectively. B) Effects of fluvoxamine on
extracellular 5-HT expressed as the AUC ± SEM for treatment periods of 0, 0.3 and 1.0
µM fluvoxamine in wildtype and 5-HT1B KO mice. Symbols: * indicates a significant
dose effect (p<0.05) and ‡ indicates a significant genotype effect (p<0.05). For vehicle
groups n=7-9 and for fluvoxamine groups n=7-8 mice. 
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Combined administration of fluvoxamine and the selective 5-HT1B receptor 
antagonist NAS-181 
The effects of concurrent administration of fluvoxamine (1 µM) and the 5-HT1B 
receptor antagonist NAS-181 (1 µM) into the PFC are shown in Fig. 3. Mice 
received either fluvoxamine for 40 minutes followed by co-perfusion of 
fluvoxamine with NAS-181 for another 180 minutes, or perfusion of NAS-181 
alone. Multivariate ANOVA revealed a time effect (F(11,374)=24.5, p < 0.001), a 
time x treatment interaction  (F(22,374)=23.0, p < 0.001), a treatment effect 
(F(1,34)=99.4, p < 0.001) and a treatment x genotype interaction (F(1,34)=4.6, p < 
0.05).  
Combined administration of fluvoxamine and NAS-181 caused a significantly 
greater increase in extracellular 5-HT in wildtype mice than in 5-HT1B KO mice 
(F(1,12)=4.9, p < 0.05). The maximum increase of extracellular 5-HT after 
combined administration of fluvoxamine and NAS-181 was 1080 ± 125 % in 
wildtype mice and 777 ± 116 % in 5-HT1B KO mice. The 5-HT levels following 
NAS-181 were not different from baseline and were not different between wildtype 
and 5-HT1B KO mice. 
 
 
Discussion 
 
The main finding of the present study is that terminal 5-HT1B autoreceptors in the 
PFC limit the 5-HT elevating effects of SSRIs. Local administration of the SSRI 
fluvoxamine evoked a greater 5-HT increase in 5-HT1B KO than in wildtype mice. 
Addition of NAS-181, a 5-HT1B receptor antagonist, augmented the effects of 
fluvoxamine on 5-HT release in the PFC of wildtype mice, but not of 5-HT1B KO 
mice. Administration of NAS-181 alone did not affect 5-HT levels in either 
genotype. Basal 5-HT levels were not different between the two genotypes. Local 
administration of the 5-HT1B receptors agonist CP93129, reduced extracellular 5-
HT in wildtype but not in 5-HT1B KO mice, confirming the absence of terminal 5-
HT1B autoreceptors in the latter genotype.  
The present data on the effects of SSRIs in 5-HT1B KO mice and in wildtype mice 
combined with a 5-HT1B receptor antagonist are in line with microdialysis studies 
in other species using 5-HT1B/1D receptor antagonists. Thus, GR127935, a mixed 
5-HT1B/1D receptor antagonist augmented the effects of SSRIs on 5-HT levels in 
the frontal cortex of guinea pigs and rats, after systemic (Gobert et al., 
1997;Roberts et al., 1998) and local administration (Hertel et al., 1999). Systemic 
administration of SB-224289, a more selective 5- HT1B receptor antagonist, also  
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augmented the systemically induced SSRI- increase of extracellular 5-HT in rat 
PFC (Gobert et al., 2000). The selective 5-HT1B receptor antagonist, NAS-181, 
augmented the effects on 5-HT release after combined administration of the SSRI 
citalopram by reversed microdialysis into rat PFC (Hjorth et al., 2000). In contrast, 
NAS-181 applied systemically or locally did not augment 5-HT levels when 
citalopram was given systemically (Hjorth et al., 2000). Thus, blockade of terminal 
5-HT1B autoreceptors does not seem to be sufficient to augment the effects of 
systemically administered SSRIs, when neuronal firing is diminished due to 
simultaneous 5-HT1A autoreceptor stimulation. The finding in the present study 
that NAS-181 alone did not affect extracellular 5-HT in wildtype mice, whereas it 
augmented the effect of locally applied fluvoxamine, supports the idea that the 
effect of 5-HT1B receptor antagonists is dependent on a endogenous tone which is 
low under basal conditions. This low endogenous tone at 5-HT1B autoreceptors in 
nerve terminals under basal conditions could also explain the finding that basal 5-
HT levels were not different in 5-HT1B KO mice from those in wildtypes. In contrast 
to this explanation, it has been shown that systemically administered NAS-181 
-80 -40 0 40 80 120 160 200
time (minutes)
100
300
500
700
900
1100
1300
%
 c
ha
ng
e 
5-
H
T
NAS-181 + fluvoxamine (+/+)
NAS-181 + fluvoxamine (-/-)
NAS-181 (+/+)
NAS-181 (-/-)
Fig 3. Combined administration of fluvoxamine and the 5-HT1B receptor antagonist
NAS-181 into the PFC. Data is expressed as mean percent of basal 5-HT levels ±
SEM. At time point zero 1.0 µM fluvoxamine was administered for 40 minutes in
wildtype (+/+) or 5-HT1B KO mice (-/-) and followed by another 160 minutes combined
with 1.0 µM NAS-181 as indicated by the bar. For wildtypes n=6-8 and for 5-HT1B KO
mice n=5-6. 
40  | CHAPTER 3 
increased 5-HT metabolism (5-HIAA/5-HT ratio) in rat frontal cortex and other 
brain areas, suggesting that terminal 5-HT1B receptors are tonicallly active under 
these conditions (Stenfors et al. 2000). Methodological differences, however, 
make it difficult to compare effects on 5-HT metabolism with in vivo microdialysis 
studies measuring 5-HT output. In wildtype mice, the regulation of 5-HT release 
by 5-HT1B receptors was shown by local administration of CP93129, resulting in 
decreased extracellular 5-HT levels.  
The present study shows that local administration of fluvoxamine resulted in a 
dose-dependent 5-HT increase that was greater in 5-HT1B KO mice than in the 
wildtype mice. This finding indicates that 5-HT1B autoreceptors play a significant 
role in the regulation of 5-HT release in the PFC. The effect on 5-HT release in the 
PFC following locally applied fluvoxamine differs from data reported for 
systemically administered SSRIs in wildtype and 5-HT1B KO mice. In a study by 
Malagie et al (2001), systemic injection of the SSRI paroxetine of 5 mg/kg, but not 
1 mg/kg, resulted in a similar 5-HT increase in 5-HT1B KO and wildtype mice and 
the effect of paroxetine was not augmented by the 5-HT1B/1D receptor antagonist 
GR127935 in the wildtypes. A possibly explanation might be that the simultaneous 
activation of somatodendritic 5-HT1A autoreceptors could have limited the effect of 
5-HT1B autoreceptors on 5-HT release following the high dosage of paroxetine. It 
should be noted that in our study, extracellular 5-HT was measured in the medial 
prefrontal cortex, whereas in the study by Malagie et al the frontal cortex was 
chosen, it can not be ruled out that 5-HT release is differentially regulated in these 
cortical areas. Regional differences of SSRI effects on extracellular 5-HT levels 
are well known (see for a review Hjorth et al. 2000) and are supported by recent 
studies in mice lacking 5-HT1A or 5-HT1B receptors (Malagie et al. 2001, 
Knobelman et al. 2001b). In keeping with this notion, a differential role of 
postsynaptic 5-HT1A receptors in the medial and lateral prefrontal cortex was 
recently suggested (Celeda et al. 2001). Interestingly, administration of 
fluvoxamine combined with a selective 5-HT1B receptor antagonist, resulted in a 
greater 5-HT increase in wildtype than in 5-HT1B KO mice. NAS-181 did not 
augment the effect of fluvoxamine in 5-HT1B KO mice, indicating that NAS-181 is a 
selective 5-HT1B receptor antagonist in wildtype mice. The differential 5-HT 
response after fluvoxamine combined with NAS-181 between the two genotypes 
suggests that possible adaptive changes in 5-HT1B KO mice might compensate for 
the loss of terminal 5-HT autoreceptors. Since the knockout mice lack 5-HT1B 
receptors throughout life, adaptive changes during neurodevelopment might have 
taken place that can explain these differences (Scearce-Levie et al., 1999, 
Castanon et al., 2000). Indeed, in some brain areas of 5-HT1B KO mice, 
alterations in 5-HT metabolism and regional changes in 5-HT transporters have 
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been demonstrated, but so far not in the frontal cortex (Ase et al., 2000, Ase et al., 
2001). In a previous study in wildtype and 5-HT1B KO mice, we found a different 
dose-response for fluvoxamine in the hippocampus after locally applied 
fluvoxamine, supporting compensatory adaptations in 5-HT1B KO mice at the level 
of the 5-HT reuptake site in this brain structure (de Groote et al., 2002a). 
Postsynaptic 5-HT1A receptors may also affect extracellular 5-HT levels (Bosker et 
al., 1997b, Hajos et al., 1999, Casanovas et al., 1999). Recently, it has been 
shown that neuronal pathways from the medial PFC endowed with 5-HT1A 
receptors projecting back to the dorsal raphe can inhibit 5-HT neuronal firing 
(Celada et al. 2001). Although binding studies show no evidence for possible 
adaptive changes (Evrard et al., 1999, Ase et al., 2001), functional changes in 
postsynaptic 5-HT1A receptors or 5-HT transporters might exist in the PFC of 5-
HT1B KO mice.  
In conclusion, terminal 5-HT1B autoreceptors in the PFC play a significant role in 
the regulation of 5-HT release. The 5-HT increase induced by local SSRI-
administration was augmented in 5-HT1B KO mice as compared to wildtype mice 
and was augmented by simultaneous administration of a 5-HT1B receptor 
antagonist in the latter genotype. In 5-HT1B KO mice, the 5-HT1B receptor 
antagonist NAS-181 did not affect extracellular 5-HT and did not further increase 
the effect of fluvoxamine, showing that NAS-181 is a selective 5-HT1B receptor 
antagonist. Finally, the greater increase in 5-HT levels following combined 
administration of a SSRI with NAS-181 in wildtype mice, as compared to 5-HT1B 
KO mice, suggests possible adaptive changes in the knockout mice. 
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Abstract 
 
In vivo microdialysis was performed in wildtype and 5-HT1B receptor knockout 
mice to explore the role of 5-HT1B receptors in striatal serotonin (5-HT) and 
dopamine (DA) outflow. Local administration of the selective 5-HT reuptake 
inhibitor fluvoxamine (0.1 – 10 µM) dose-dependently increased 5-HT to the same 
extent in wildtype and 5-HT1B receptor knockout mice. The 5-HT1B receptor 
agonist CP93129 (0.5 µM) reduced 5-HT levels wildtype mice, but did not affect 
DA outflow. Striatal DA outflow was increased 5-fold by 50 µM CP93129, in 
wildtypes and surprisingly, 5-HT1B receptor knockout mice showed an identical 
response. The CP93129-induced DA increase was not attenuated by ritanserin, a 
5-HT2A/2C receptor antagonist, but was completely blocked by tetrodotoxin, 
demonstrating that the DA release was from a neuronal origin. Increased striatal 
5-HT levels should indirectly activate 5-HT receptors that facilitate DA release. 
The 5-HT releaser fenfluramine (50 µM) and the SSRI fluvoxamine (10 µM) both 
increased 5-HT and DA levels, but their effect was not different between the 
genotypes.  
Concluding, striatal 5-HT1B autoreceptors are functionally present, but do not play 
a significant role in the effects of SSRIs on extracellular 5-HT. The results in 5-
HT1B knockout mice do not support a role of striatal 5-HT1B heteroreceptors in DA 
outflow in the striatum.  
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Introduction 
 
It has been well established that serotonin (5-HT) modulates dopamine (DA) 
neurotransmission (Soubrie et al., 1984, Bonhomme et al., 1995). Thus, the 
striatonigral pathway is innervated by serotonergic afferents both at dopaminergic 
nerve terminals in the striatum and at dopaminergic cell bodies in the substantia 
nigra (Steinbusch, 1981). Anatomical data suggest a role for 5-HT1B receptors in 
the interactions between 5-HT and DA pathways, because this receptor is 
positioned at sites where it can modulate both 5-HT and DA release in the 
striatum (Bruinvels et al., 1994, Sari et al., 1999). Anatomical studies have also 
shown that 5-HT1B receptors are abundantly present in the caudate putamen and 
in the substantia nigra, whereas mRNA for 5-HT1B receptors was not detected in 
the latter brain structure (Boschert et al., 1994). The mismatch between binding 
sites and mRNA has led to the idea that 5-HT1B heteroreceptors are present on 
GABA-ergic afferents projecting from the striatum to the substantia nigra. This is 
supported by electrophysiological studies showing that stimulation of 5-HT1B 
receptors inhibits GABA release from terminals that innervate DA neurons in the 
substantia nigra, resulting in disinhibition of DA neurons (Johnson et al., 1992, 
Cameron and Williams, 1994, Morikawa et al., 2000). Furthermore, there is 
neurochemical evidence that striatal DA release is modulated by 5-HT. In vivo 
microdialysis studies have shown increased DA outflow when striatal 5-HT levels 
are enhanced by exogenous applied 5-HT (Benloucif and Galloway, 1991, Yadid 
et al., 1994, Bonhomme et al., 1995) or by the 5-HT releaser fenfluramine (De 
Deurwaerdere et al., 1995, Baumann et al., 2001). Studies in rats using 5-HT1B 
receptor agonists indicated that 5-HT1B receptors facilitate DA release in the 
dorsal striatum (Benloucif et al., 1993, Galloway et al., 1993, Bentue-Ferrer et al., 
1998, Ng et al., 1999). Furthermore, in striatal synaptosomes, activation of 5-HT1B 
receptor with CP93129, a 5-HT1B receptor agonist, modulates DA release in 
wildtype mice, whereas this effect was absent in mice lacking 5-HT1B receptors, 
supporting a role of 5-HT1B receptors in striatal DA release (Sarhan et al., 2000).  
In the CNS, 5-HT1B receptors are also present as inhibitory autoreceptors on 
serotonergic nerve terminals. Activation of 5-HT1B autoreceptors reduces striatal 
5-HT levels in rat (Abellan et al., 2000) and mouse (Knobelman et al., 2000). The 
5-HT1B receptor knockout mouse is an interesting model to further explore the role 
of 5-HT1B receptors in the modulation of striatal 5-HT and DA release. In the 
absence of terminal 5-HT1B autoreceptors, increased 5-HT levels might be 
expected following administration of selective 5-HT reuptake inhibitors (SSRIs). In 
mice lacking 5-HT1B receptors, however, no difference in striatal 5-HT was found 
after systemic administration of the SSRI fluoxetine as compared to wildtype mice 
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(Knobelman et al., 2001a). Involvement of 5-HT1B receptors in an interaction 
between 5-HT and DA pathways is supported by studies in 5-HT1B KO mice 
showing that DA neurotransmission is altered in 5-HT1B KO mice (Scearce-Levie 
et al., 1999, Ase et al., 2000). 5-HT1B KO mice are more vulnerable to 
dopaminergic drugs like cocaine (Lucas et al., 1997, Rocha et al., 1998), 
although, cocaine-evoked DA levels in the striatum were not different between 
wildtype and 5-HT1B KO mice (Shippenberg et al., 2000). There are thus, no in 
vivo studies that have examined the effects of serotonergic intervention on DA 
outflow in mice lacking 5-HT1B receptors.  
In the present study, in vivo microdialysis was used to examine the role of striatal 
5-HT1B receptors in 5-HT and DA outflow by comparing wildtype with 5-HT1B KO 
mice. The effects on striatal 5-HT and DA were measured following local 
administration of different serotonergic drugs. CP93129, a selective 5-HT1B 
receptor agonist, was used to stimulate 5-HT1B receptors and the SSRI 
fluvoxamine and the 5-HT releaser fenfluramine were used to enhance 5-HT 
levels. 
 
 
Material and Methods 
 
Animals 
In this study, male wildtype and 5-HT1B knockout mice on a 129/SV genetic 
background were tested (Saudou et al., 1994). The mice were housed eight 
animals per cage, kept on a 12-hour light-dark cycle (6 a.m. on, 6 p.m. off) at 
constant room temperature (22 ± 2°C), controlled humidity 40 - 60 %) and free 
access to food and water. At the time of the experiments, the mice were at an age 
between 12-16 weeks and 25-35 grams. The mice were bred in separate 
homozygous lines in the animal facilities, GDL, Utrecht, The Netherlands. 
Offspring from the two breeding lines were regularly screened to confirm their 
genotype. Due to the unexpected findings with 50 µM CP93129, genotypes of 
mice from these groups were screened after the experiments. The original 
wildtype and knockout mice were obtained from Dr. René Hen, Columbia 
University, New York, USA. The ethical committee for animal research of the 
University Medical Center Utrecht, The Netherlands, approved all studies. 
 
Microdialysis procedure  
Microdialysis probes were implanted in the dorsal striatum under chloralhydrate 
anaesthesia (400 mg/kg, i.p.) and lidocaine (2%) applied on the skull. For surgery, 
the mice were placed in a stereotaxic frame using a mouse adaptor (Kopf, 
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Germany) with modified earbars. During surgery mice were kept warm on a 
heating pad. A concentric self-constructed microdialysis probe with an AN filtral 69 
membrane, outer diameter 310 µM (Hospal, Uden, The Netherlands), was placed 
in the dorsal striatum according to the stereotaxic atlas of the mouse brain 
Franklin and Paxinos, 1997. The coordinates were: AP +0.80, ML –1.7 mm from 
bregma, DV –4.0 mm from the dura, with the toothbar set at 0 mm. The active 
dialysis surface length of the membrane was 2 mm. The probe was secured in 
place with dental cement and two anchor screws in the skull. After surgery mice 
were injected with saline (0.5 ml i.p.) to prevent dehydration and the mice were 
housed separately. Microdialysis experiments started 16-20 hours after surgery. 
Ringer solution (147 mM NaCl, 2.3 mM KCl,  2.3 mM CaCl2, 1.0 mM MgCl2) was 
perfused through the microdialysis probe with a flow at 1.13 µl/min using a high 
precision pump (Harvard PHD2000, Harvard Scientific, USA). Mouse swivels 
(Type 375/25, Instech Laboratories, Inc, USA) connected to PEEK-tubing (ID 
0.005”, OD 0.020”) were used to allow unrestrained movements of the mice. After 
the start of the dialysis probe perfusion, mice were left undisturbed for three 
hours. Mice were tested in their homecage during the light period. Samples were 
collected every 20 minutes in vials containing 7.5 µl acetic acid and stored at –
80°C until HPLC analysis. At the end of the experiment the mice were killed by 
cervical dislocation, the brains were removed and fixed in 4% formaldehyde 
solution. To verify the position of the probe the brains were cut in 50 µm slices on 
a vibratome. In case of improper probe placement, data was excluded.  
 
Drugs 
The following drugs were used; CP93129 dihydrochloride (1,4-Dihydro-3-(1,2,3,6-
tetrahydro-4-pyridinyl)-5H-pyrrolo[3,2-b]pyridin-5-one, obtained from Tocris, UK), 
fluvoxamine maleate (donated by Solvay Pharmaceuticals, The Netherlands), 
ritanserin (Janssen Life Sciences Products, Belgium), S(+)-fenfluramine 
hydrochloride (RBI, Natick, M.A, USA) and tetrodotoxin (Sigma, St. Louis, USA). 
All drugs, except ritanserin, were dissolved in distilled water and further diluted in 
Ringer solution to the final concentration on the day of the experiment. Ritanserin 
was first dissolved in a drop of acetic acid, further diluted to the final concentration 
and the pH was adjusted to that of Ringer solution. 
 
HPLC-ECD analysis 
5-HT, DA and their metabolites were analyzed by HPLC with electrochemical 
detection. Samples (25 µl) were injected onto an Inertsil ODS-3 column (3 µM, 
2.1x100mm, Aurora Borealis, The Netherlands) using a Gilson pump and 
autosampler (Separations, The Netherlands). Separation was performed at 40ºC 
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with an electrochemical detector (Intro, ANTEC Leyden, The Netherlands) set at a 
potential of 600 mV against an Ag/AgCl reference electrode. The signal was 
analyzed using Gynkotek software. The mobile phase consisted of 5 g/l 
(NH4)2SO4, 150 mg/l heptane sulphonic acid sodium salt, 0.5 g/l EDTA, 5% 
methanol, 30 µl/l triethylamine, 30 µl/l acetic acid, pH 4.6. Flow rate was 0.3 
ml/min. The detection limit for 5-HT was 0.5 fmol/25 µl sample (signal to noise 
ratio 2).  
 
Data analysis and statistics 
Values for the first four consecutive samples were averaged to calculate the basal 
levels of extracellular 5-HT and DA, uncorrected for probe recovery. Student’s t-
tests were used to compare basal 5-HT and DA values between the two 
genotypes. In the figures, all 5-HT or DA levels are expressed as percentages of 
basal levels ± SEM. Effects of drug treatment were analyzed by a repeated 
multivariate analysis of variance (ANOVA) with time as ‘within’ and treatment (or 
dose) and genotype as ‘between’ factors. When appropriate, data were broken 
down and pairwise comparisons were made. To test the concentration effects of 
fluvoxamine, area under the curve (AUC) values were calculated for the 200 min 
infusion period of vehicle (Ringer solution) and the different fluvoxamine 
concentrations. AUC values were analyzed with ANOVA with dose and genotype 
as ‘between’ subject factors. When appropriate, data was broken down on 
genotype and post-hoc comparisons with Bonferroni corrections were made. The 
significance level for all analyses was set at 5%. In the figures the start of local 
infusion (time point zero) of drugs is corrected for the dead volume of the 
microdialysis system. 
 
 
Results 
 
Basal levels 
Basal levels of extracellular 5-HT and DA levels in the dorsal striatum were not 
different between wildtype and 5-HT1B KO mice. Basal 5-HT levels were 4.0 ± 0.3 
fmol/sample in wildtype (n = 51) and 5.0 ± 0.6 fmol/sample in 5-HT1B KO mice (n = 
45). Basal DA levels were 181.3 ± 14.6 fmol/sample in wildtype (n = 51) and 183.1 
± 15.9 fmol/sample in 5-HT1B KO mice (n = 45). 
 
Effects of fluvoxamine and CP93129 on 5-HT outflow 
Local administration of the SSRI fluvoxamine into the striatum increased 5-HT 
levels dose-dependently as shown in Fig.1. Three concentrations of fluvoxamine 
48 | CHAPTER 4 
Fig.1. Effects of local administration
of fluvoxamine into the dorsal
striatum on extracellular 5-HT. Data
are expressed as the mean percent
change from basal 5-HT levels ±
SEM. Time course of the effects of
fluvoxamine at concentrations of 0.1,
1.0 and 10 µM in wildtype mice (A)
and 5-HT1B KO mice (B). Effects of
fluvoxamine expressed as AUC ±
SEM (C). Symbol: * indicates a
significant dose effect compared to
vehicle within genotype (P < 0.05). 
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were administered by reversed microdialysis. A repeated measures ANOVA 
indicated an effect of time x dose (F(27,333 )= 18.4, P < 0.001), of dose (F(1,37)=  
72.6, P < 0.001), but not of genotype (F(1,37)= 0.14, P = 0.9). Fluvoxamine at 
concentrations of 0.1, 1.0 and 10 µM increased 5-HT to about 3, 6 and 8-fold, 
respectively. The dose-response to fluvoxamine was similar in wildtype and 5-
HT1B KO mice. Taking the AUC as outcome variable similar results were obtained 
(Fig.1C). Post-hoc comparison of the dose effects of fluvoxamine within genotype 
indicated significant effects between 1.0 and 10 µM fluvoxamine as compared to 
vehicle (P < 0.001), but not between vehicle and 0.1 µM fluvoxamine (P = 0.29 
and P = 0.18 for wildtype and 5-HT1B KO mice, respectively). Furthermore, 
significant effects were found between the concentrations of 0.1, 1.0 and 10 µM 
fluvoxamine (P < 0.01), except for the 1.0 µM versus the 10 µM group in 5-HT1B 
KO mice (P = 0.062).  
Local administration of the 5-HT1B receptor agonist, CP93129, decreased 5-HT 
levels in wildtype, but not in 5-HT1B KO mice as shown in Fig.2. A repeated 
measures ANOVA indicated an effect of treatment (F(1,17)= 6.2, P < 0.05) and of 
genotype (F(1,17)= 13.5, P < 0.01). In wildtype mice, CP93129 (0.5 µM) reduced 
5-HT to 51 ± 9 % as compared to vehicle (F(1,10)= 11.2, P < 0.01). 
 
Effects of CP93129 on striatal DA outflow 
Local administration of 50 µM CP93129 into the striatum increased DA levels, 
whereas 0.5 µM did not affect DA outflow as shown in Fig.3A. A repeated 
measures ANOVA indicated an effect time x dose (F(16, 256)= 7.9, P < 0.001), of 
dose (F(2,32)= 55.6, P < 0.001), but not of genotype (F(2,32)= 0.5, P = 0.98). 
Fig.2. Effects of local administration
of the 5-HT1B receptor agonist
CP93129 into the dorsal striatum on
5-HT outflow in wildtype (WT) and 5-
HT1B KO mice (KO). Data are
expressed as the mean percent
change from basal level ± SEM.
Time course of 0.5 µM CP93129
(black bar) administered for 120
minutes. For clarity reasons vehicle
groups are not shown. 
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Fig.3. Effects of local administration
of the 5-HT1B receptor agonist
CP93129 into the dorsal striatum on
DA outflow in wildtype (WT) and 5-
HT1B KO mice (KO). Data are
expressed as the mean percent
change from basal level ± SEM.
Time course of 0.5 µM and 50 µM
CP93129 (black bar) administered
for 120 minutes in wildtype and 5-
HT1B KO mice (A). Time course of
local infusion of 10 and 100 µM of
the 5-HT2A/2C receptor antagonist
ritanserin (open bar) for 60 minutes
followed by co-perfusion with 50 µM
CP93129 (black bar) in wildtype
mice (B). Time course of local
infusion of 50 µM CP93129 minutes
and co-perfusion with tetrodotoxin
(TTX, black bar) for 60 minutes (C). 
-60 0 60 120 180
time (min)
100
300
500
700
%
 c
ha
ng
e 
D
A
WT 50 µM CP (n=8)
KO 50 µM CP (n=8)
WT 0.5 µM CP (n=6)
KO 0.5 µM CP (n=5)
A
CP93129
-60 0 60 120 180
time (min)
100
300
500
700
%
 c
ha
ng
e 
D
A
WT CP93129/TTX (n=4)
KO CP93129/TTX KO (n=2)
1 µM TTX
C
50 µM CP93129
-60 0 60 120 180
time (min)
100
300
500
700
%
 c
ha
ng
e 
D
A
WT 10 µM ritanserin (n=3)
WT 100 µM ritanserin (n=4)
ritanserin
B
CP93129
5-HT/DA interaction in the striatum | 51 
CP93129 (50 µM) increased DA levels in 5-HT1B KO mice to the same extent as in 
wildtypes when compared to vehicle (P < 0.001). The CP93129-induced increases 
were 525 ± 79 % and 527 ± 67 % in wildtype and 5-HT1B KO, respectively.  
To test the involvement of 5-HT2 receptors in the effect of CP93129, the 5-HT2A/2C 
receptor antagonist ritanserin was administered starting 60 minutes before 
CP93129 was co-perfused. In wildtype mice, the increase in striatal DA induced 
by 50 µM CP93129 was not affected by ritanserin (10 or 100 µM) as shown in 
Fig.3B. To test the neuronal origin of the CP93129-induced DA release, the 
sodium potassium channel blocker tetrodotoxin was co-perfused with CP93129.  
 
 
 
 
 
 
 
 
Fig.4. Effects of the 5-HT releaser
fenfluramine on striatal 5-HT and DA
outflow in wildtype (WT) and 5-HT1B KO 
mice (KO). Data are expressed as the
mean percent change from basal level
± SEM. Time course of the effects 50
µM fenfluramine locally applied into the
striatum for 120 minutes (black bar) on
5-HT outflow (A) and DA outflow (B).
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Effects of 5-HT on DA outflow  
Local administration of the 5-HT releaser fenfluramine increased 5-HT and DA 
levels as shown in Fig.4. For the effects of fenfluramine on 5-HT outflow, a 
repeated measures ANOVA indicated an effect of treatment (F(1,18)= 62.6, P < 
0.001), but not of genotype  (F(1,18)= 0.01, P = 0.9). Fenfluramine (50 µM) as 
compared to vehicle, significantly increased 5-HT levels to the same extent in both 
genotypes (P < 0.001). The mean maximum increases in 5-HT following 
fenfluramine were 1047 ± 134 % and 1122 ± 167 % in wildtype and 5-HT1B KO 
mice, respectively. For the effects of fenfluramine on DA outflow, a repeated 
measures ANOVA indicated an effect of treatment (F(1,17)= 19.5, P < 0.001), but 
not of genotype (F(1,17)= 0.04, P = 0.8). Fenfluramine (50 µM) as compared to 
vehicle, significantly increased 5-HT levels to the same extend in wildtype (P < 
0.01) and 5-HT1B KO mice (P < 0.5). After 80 minutes infusion, the DA outflow in 
response to fenfluramine was increased to a mean maximum of 213 ± 15% and 
188 ± 14 % in wildtype and 5-HT1B KO mice, respectively.  
As shown in Fig.1, 10 µM fluvoxamine increased 5-HT levels to ~ 800 % of 
baseline. Fig.5. shows the effect of 10 µM fluvoxamine on DA outflow. A repeated 
measures ANOVA indicated an effect of treatment (F(1,18)= 31.0, P < 0.001), but 
not of genotype (F(1,18)= 0.5, P = 0.5). Fluvoxamine (10 µM) significantly 
increased DA outflow as compared to vehicle to the same extent in both 
genotypes, to a mean maximum of 148 ± 13 % in wildtype (P < 0.001) and to 139 
± 18 % in 5-HT1B KO mice (P < 0.01). 
 
 
Fig.5. Effects of the SSRI
fluvoxamine on DA outflow in
wildtype (WT) and 5-HT1B KO mice
(KO). Data are expressed as the
mean percent change from basal
level ± SEM. Time course of the
effects of 10 µM fluvoxamine (open
bar) on striatal DA outflow. 
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Discussion 
 
The present study confirms the presence of 5-HT1B autoreceptors in the dorsal 
striatum of mice, but also shows that these 5-HT autoreceptors do not play a 
prominent role in the effects of a locally applied SSRI on 5-HT release. The 
previous reported role of 5-HT1B heteroreceptors on striatal DA outflow could not 
be confirmed in this study. The putative selective 5-HT1B receptor antagonist 
CP93129 increased striatal DA levels to the same extent in wildtype and in 5-HT1B 
KO mice, indicating that the effect of CP93129 was not mediated by 5-HT1B 
receptors. Furthermore, the 5-HT induced extracellular DA increase by 
fenfluramine and fluvoxamine administration was not different between the two 
genotypes. 
In line with other studies, we found that basal extracellular levels of 5-HT and DA 
in the dorsal striatum were not different between wildtype and 5-HT1B KO mice 
(Knobelman et al., 2001, Shippenberg et al., 2000). This suggests that, either 5-
HT1B receptors do not affect 5-HT and DA release in the striatum under basal 
conditions, or that compensatory effects may have taken place during 
neurodevelopment. Moreover, no genotype difference was found in the effects on 
5-HT levels following local administration of a SSRI into the striatum, suggesting 
that 5-HT1B autoreceptors do not limit these SSRI effects. This is in line with a 
previous study that showed a similar striatal 5-HT increase in wildtype and 5-HT1B 
KO mice upon systemic SSRI administration, although involvement of 
somatodendritic 5-HT1A autoreceptors may account for this systemic effect 
(Knobelman et al., 2001). In contrast to the effects in the striatum, we previously 
reported augmented 5-HT responses after locally applied fluvoxamine (1 µM) into 
the hippocampus and prefrontal cortex of 5-HT1B KO mice (de Groote et al., 
2002a, 2002b). Densities of 5-HT transporters are about two times higher in the 
striatum as compared to hippocampal or cortical areas of mice (Bengel et al., 
1997). Possibly, extracellular 5-HT is more efficiently removed by 5-HT 
transporters in the striatum relative to other brain areas. This might also explain 
why basal levels of 5-HT were not different between 5-HT1B KO and wildtype 
mice. Interestingly, in a study by Tao et al (2000) local administration of a high 
concentration of the SSRI citalopram (100 µM) into the nucleus accumbens was 
augmented by (-)-penbutolol, a non-selective 5-HT1B receptor antagonist. This 
might suggest that terminal 5-HT1B autoreceptors affect 5-HT release only when 5-
HT reuptake sites are maximally blocked in striatal areas, although non-selective 
effects on 5-HT of (-)-penbutolol can not be excluded. Whether 10 µM fluvoxamine 
in our study maximally blocked striatal 5-HT reuptake sites is unclear, but in view 
of the observed 8-fold 5-HT increase it is unlikely that the absence of an 
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augmented 5-HT response in 5-HT1B KO mice is accounted by insufficient 
reuptake blockade. Nevertheless, infusion of CP93129 (0.5 µM) reduced 5-HT 
levels in wildtype mice, indicating that 5-HT1B autoreceptors are functionally 
present in the striatum in this genotype.  
The 5-HT1B receptor agonist CP93129, in a concentration range of 10-500 µM, 
has been reported to increase DA outflow in rat striatum (Benloucif et al., 1993, 
Galloway et al., 1993, Bentue-Ferrer et al., 1998) and other brain structures (Iyer 
and Bradberry, 1996, Yan and Yan, 2001). This effect of CP93129 on DA outflow 
has been attributed by stimulation of 5-HT1B heteroreceptors. In the present study, 
however, DA outflow increased to the same extent in wildtype and 5-HT1B KO 
mice following administration of 50 µM CP93129. The present results, therefore, 
demonstrate that the DA increase induced by CP93129 is not mediated through 5-
HT1B receptors. Thus, rat studies in which the effects of CP93129 on striatal DA 
outflow are attributed to stimulation of 5-HT1B heteroreceptors should be 
reconsidered (Benloucif et al., 1993, Galloway et al., 1993, Bentue-Ferrer et al., 
1998). CP93129 also has affinity for 5-HT1D, 5-HT1A and 5-HT2C receptor subtypes 
(Macor et al., 1990). Based on the affinity profile of CP93129 and the expression 
of 5-HT2A/2C receptors in the striatum, we choose ritanserin, a 5-HT2A/2C receptor 
antagonist, to investigate whether the effects of CP93129 may be accounted by 
stimulation of these receptor subtypes. Co-perfusion with ritanserin did not 
attenuate the effect of CP93129 on DA outflow, suggesting that 5-HT2A/2C receptor 
subtypes are not implicated. The effect of CP93129 on DA outflow was blocked by 
co-perfusion with tetrodotoxin, indicating that the DA release induced by CP93129 
was from neuronal origin. There is circumstantial evidence that 5-HT3 and 5-HT4 
receptor subtypes can also affect DA outflow (Bonhomme et al., 1995, Lucas et 
al., 2001). Possibly, CP93129 exerts its effect on DA outflow through stimulation 
of 5-HT3 or 5-HT4 receptors, although to our knowledge, affinity of CP93129 for 
these receptor subtypes has not been reported.  
A locally applied 5-HT releaser or a SSRI into the striatum increased both 5-HT 
and DA levels. These findings are consistent with the idea that 5-HT modulates 
striatal DA outflow. Nevertheless, it can not be excluded that the effects of 
fenfluramine or fluvoxamine on DA outflow involve other effects of these 
compounds. It has been suggested that fenfluramine is not a very useful tool to 
study 5-HT and DA interactions since its effect on DA outflow in the striatum was 
still present after lesioning the serotonergic system in rats (De Deurwaerdere et 
al., 1995).  
In the present study, no evidence for a role of 5-HT1B receptors in striatal DA 
outflow was found. This does not exclude modulation of striatal DA release by 5-
HT1B receptors. Enriched binding densities for 5-HT1B receptors are found in the 
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substantia nigra, and these receptors are thought to play a role in the regulation of 
DA neuronal activity. Interestingly, a microdialysis study in the substantia nigra 
reported an increase of DA outflow to 4770% following 1 µM CP93129, suggesting 
that low doses of CP93129 may activate 5-HT1B heteroreceptors in this brain 
structure (Thorre et al., 1998). Another possible explanation for the lack of effect 
of striatal 5-HT1B heteroreceptors on DA outflow in the striatum, could be that 
interactions between 5-HT and DA neurotransmission are not elicited by activation 
of striatal 5-HT1B receptors under basal conditions. There is evidence to suggest 
that stimulation of striatal 5-HT induced by low concentrations of SSRIs, increase 
DA outflow only when the striatonigral pathway is activated (Lucas et al., 2000).  
Concluding, striatal 5-HT1B autoreceptors are functionally present in the striatum, 
but do not play a significant role in the effects of a locally applied SSRI on 5-HT 
levels. The results support an interaction between 5-HT and DA neurotransmisson 
in the striatum, but this interaction is not mediated by striatal 5-HT1B 
heteroreceptors.
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Abstract 
 
In the mammalian brain 5-HT1B receptors are present as autoreceptors regulating 
the release of serotonin (5-HT) by inhibitory feedback. The antagonistic properties 
of NAS-181, a new selective antagonist for the rodent 5-HT1B receptor, was 
determined by using an agonist-induced decrease of extracellular 5-HT. The 5-
HT1B receptor agonist CP93129 (0.03–0.3 µM) applied by reversed microdialysis, 
dose-dependently reduced 5-HT levels in rat frontal cortex. The suppressant 
effect of CP91239 (0.1 µM) was smaller in the presence of fluvoxamine (3-10 µM), 
a 5-HT reuptake inhibitor. The effects of NAS-181 on CP93129 were compared 
with GR127935, a mixed 5-HT 1B/1D receptor antagonist, and SB224289, a 5-HT1B 
receptor antagonist. Both in the presence and absence of fluvoxamine, the 
suppressant effect of CP93129 on extracellular 5-HT was attenuated by NAS-181 
(1 µM) and GR127935 (10 µm), but not by SB224289 (1 µM). In the absence of 
fluvoxamine, GR127935, SB224289 and NAS-181 all reduced 5-HT levels, 
suggesting partial agonistic properties of these compounds. In conclusion, the 
results show that NAS-181 is a potent 5-HT1B receptor antagonist. 
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Introduction 
 
5-HT1B receptors are expressed throughout the mammalian brain, either as 
autoreceptors or heteroreceptors, with high densities in the basal ganglia, limbic 
and cortical areas (Boschert et al., 1994, Bruinvels et al., 1993). The release of 5-
HT is regulated by 5-HT1B autoreceptors on serotonergic nerve terminals (Engel et 
al., 1986, Maura et al., 1986). The rodent and human 5-HT1B receptor are 
considered as species homologues based on their similar function and amino acid 
homology (Adham et al., 1992, Hoyer and Middlemiss, 1989). Rodent 5-HT1B 
autoreceptors are pharmacologically different from the human and guinea pig 5-
HT1B receptor (formerly known as 5-HT1Dß) (Hartig et al., 1992). This species 
difference in pharmacology is mainly based on the affinity of rodent 5-HT1B 
receptor for ß-adrenergic compounds and is due to a single amino acid difference 
(Oksenberg et al., 1992). Research on 5-HT1B receptors has been complicated 
due to a lack of selective antagonists. Most compounds that have been used to 
study 5-HT1B receptors so far are not selective for 5-HT1 receptor subtypes or had 
additional affinity for other bi 
nding sites. Recently, more selective 5-HT1B receptor antagonists have become 
available. GR127935 is a selective antagonist for both rodent and human 5-HT1B 
receptors, although it does not discriminate between 5-HT1B and 5-HT1D receptor 
subtypes (Hutson et al., 1995). SB224289 is a more selective 5-HT1B receptor 
antagonist (Gobert et al., 2000). Despite their selectivity, GR127935 and 
SB224289 have been reported to display partial or inverse agonist properties at 
human 5-HT1B and 5-HT1D receptors, although there is as yet no in vivo evidence 
for such properties (Pauwels, 1997, Millan et al., 1999). NAS-181 is a new 
selective 5-HT1B receptor antagonist for rodent 5-HT1B receptors (Berg et al., 
1998) and has been shown to increase 5-HT metabolism and synthesis (Stenfors 
et al., 2000). Microdialysis studies on the effects of 5-HT1B receptor antagonists on 
extracellular 5-HT have resulted in some conflicting findings. Whereas stimulation 
of 5-HT1B receptors decreases extracellular 5-HT levels (Hjorth and Tao, 1991, 
Bosker et al., 1995, Adell et al., 2001), administration of 5-HT1B receptor 
antagonists does not seem to affect 5-HT levels (Roberts et al., 1998). 
Systemically administered GR127935 has been found to decrease 5-HT levels in 
guinea pig frontal cortex, but this effect was explained by activation of 5-HT1B/1D 
receptors in the raphe nuclei (Roberts et al., 1998). Blockade of 5-HT1B receptors 
has been reported to augment the effect of systemic SSRIs on 5-HT levels in the 
frontal cortex (Gobert et al., 1997 Dawson and Nguyen, 2000, Hervas et al., 2000, 
Gobert et al., 2000), but not in all studies (Sharp et al., 1997). Following systemic 
administration of SSRIs, cell body 5-HT1A autoreceptors may limit the effects of 5-
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HT1B receptors in serotonergic projection areas. To exclude effects of 5-HT 
receptors in the raphe on 5-HT output, antagonists can be applied locally into 
serotonergic projection areas by reversed microdialysis. Local infusion of 
GR127935 or NAS-181 has been reported to enhance 5-HT levels in the presence 
of a SSRI in the perfusion fluid (Hertel et al., 1999, Hjorth et al., 2000). It has been 
hypothesized that terminal 5-HT1B receptors have a low basal endogenous activity 
and that effects of a 5-HT1B receptor antagonist are only elicited when 5-HT levels 
are enhanced, i.e. in the presence of a SSRI (Hjorth, 1993). 
In the present study, NAS-181 was compared with GR127935 and SB224289, two 
other selective 5-HT1B receptor antagonists. The antagonists were locally applied 
into rat frontal cortex and their properties to block the suppressant effect of the 5-
HT1B receptor agonist CP93129 on extracellular 5-HT were assessed. The effects 
of the three antagonists co-perfused with CP93129 were studied both in the 
absence and presence of the SSRI fluvoxamine in the perfusion fluid.  
 
 
Material and methods 
 
Animals  
Male Wistar rats (GDL, Utrecht, The Netherlands) weighing 250-300 gram were 
housed three per cage at standard conditions (22-24 ºC, food and water ad lib) 
and at a 12-hour light/dark cycle (7 a.m. on, 7 p.m. off). The Ethical Committee for 
Animal Research of the University Medical Center Utrecht, The Netherlands, 
approved the study.  
 
Microdialysis procedure  
Rats were anaesthetized with chloral hydrate (400 mg/kg i.p.). A self-constructed 
concentric microdialysis probe with an AN 69 Filtral membrane (Hospal, Uden, the 
Netherlands) was stereotaxically implanted in the frontal cortex. The probe was 
positioned in the frontal cortex using the following coordinates: AP + 3.7, ML –2.6 
and DV –5.5 mm from bregma (Paxinos and Watson, 1982). The active dialysis 
surface length of the probes was 2 mm (outer diameter 310 µM). The probes were 
secured in place with dental cement. Microdialysis experiments started 16-20 
hours after surgery. Probes were perfused with Ringer solution (147 mM NaCl, 2.3 
mM KCl,  2.3 mM CaCl2, 1.0 mM MgCl2) at a constant flow of 1.5 µl/min with a 
high precision pump (Harvard Scientific, USA). Probes were connected with PE-
tubing to swivels (Instech Laboratories, USA) to allow unrestrained movements of 
the rats. After the start of the dialysis perfusion animals were left undisturbed for 
two hours before collection of samples started. Samples were collected every 15 
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min in vials containing 7.5 µl acetic acid. Until HPLC analysis, samples were 
stored at –80°C. At the end of the experiment the rats were deeply anaesthetized 
with chloral hydrate. After decapitation brains were removed and fixed in 4% 
formaldehyde solution. To verify the position of the probe the brains were cut in 50 
µm slices on a vibratome. In case of improper probe placement, data was 
excluded. 
 
HPLC-ECD analysis  
5-HT was analyzed by HPLC with electrochemical detection. Samples were 
injected onto an Inertsil ODS-3 column (3 µM, 2.1x100mm, Aurora Borealis, The 
Netherlands) using a Gilson pump and autosampler (Separations, The 
Netherlands). Separation was performed at 40ºC with an electrochemical detector 
(Intro, ANTEC Leyden, The Netherlands) set at a potential of 600 mV against an 
Ag/AgCl reference electrode. The signal was analyzed using Gynkotek software. 
The mobile phase consisted of 5 g/l (NH4)2SO4, 150 mg/l heptane sulphonic acid 
sodium salt, 0.5 g/l EDTA, 5% methanol, 30 µl/l triethylamine, 30 µl/l acetic acid, 
pH 4.6. Flow rate was 0.3 ml/min. The detection limit for 5-HT was 0.5 fmol/25 µl 
sample (signal to noise ratio 2). 
 
Drugs and experimental design 
The following drugs were used; CP93129 dihydrochloride (1,4-Dihydro-3-(1,2,3,6-
tetrahydro-4-pyridinyl)-5H-pyrrolo[3,2-b]pyridin-5-one, obtained from Tocris, UK), 
fluvoxamine maleate (donated by Solvay Pharmaceuticals, The Netherlands) and 
NAS-181 ((R)-(+)-2-[[[3-(Morpholinomethyl)-2H-chromen-8-yl]oxy]methyl] morpho-
line methane sulfonate, obtained from AstraZeneca, Sweden), GR127935 (2'-
methyl-4'-(5-methyl[1,2,4]oxadiazol-3-yl)biphenyl-4-carboxylic acid [4-methoxy-3-
(4-methylpiperazin-1-yl)phenyl]amide, obtained from Solvay Pharmaceuticals, The 
Netherlands) and SB224289 (1'-methyl-5-(2'-methyl-4'-(5-methyl-1,2,4-oxadiazole-
3-yl) biphenyl-4-carbonyl)-2,3,6,7 tetrahydrospiro [furo[2,3-f]indole-3-spiro-4'-
piperidine,  obtained from GlaxoSmithkline, UK). All drugs were first dissolved in 
distilled water and further diluted in Ringer solution on the day of the experiment. 
CP93129 was applied for 45 minutes. The administration of the receptor 
antagonists started 15 min before CP93129 was co-perfused and lasted until the 
end of the sampling period. For the fluvoxamine groups, the SSRI was present in 
the Ringer solution from the start of dialysis. 
 
Data analysis and statistics  
Values for the first four consecutive samples were averaged to calculate the basal 
levels of extracellular 5-HT, uncorrected for probe recovery. In the figures, all 5-
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HT values are expressed as percentages of basal levels ± SEM. Effects of 5-HT 
response to drug treatment were analyzed by multivariate analysis of variance 
(ANOVA) for repeated measurements with time as ‘within’ and treatment (or dose) 
as ‘between’ factors. When appropriate, data were broken down on treatment (or 
dose) and pairwise comparisons were made of the time profiles between the 
treatment groups (or dose effects). The significance level for all analyses was set 
at 5%. In the figures showing time course, the start of local infusion (time point 
zero) of drugs is corrected for the dead volume of the microdialysis system. 
 
 
Results 
 
Activation of 5-HT1B receptors reduces cortical 5-HT levels 
Local administration of the 5-HT1B receptor agonist CP93129 into the frontal 
cortex dose-dependently reduced 5-HT levels (Fig.1A). A repeated measures 
ANOVA indicated an effect of time (F(9,234)= 11.8, P < 0.001), a time x dose 
interaction (F(3,234)= 9.6, P < 0.001) and a dose effect (F(3,26)= 11.8, P < 
0.001). The levels of 5-HT were significantly reduced as compared to vehicle at 
CP93129 concentrations of 0.1 µM (F(1,16)= 23.7, P < 0.001) and 0.3 µM 
(F(1,15)= 19.6, P < 0.001), but not at 0.03 µM (F(1,15)= 3.1, P = 0.10). Cortical 5-
HT levels were reduced by CP93129 to a minimum of 45 ± 4.3 % and 50 ± 7.9 % 
of basal levels, at concentrations of 0.1 and 0.3 µM, respectively.  
In the presence of the SSRI fluvoxamine, 0.1 µM CP93129 reduced 5-HT levels at 
concentrations of 3 and 10 µM, but not at 30 µM fluvoxamine (Fig.1B). A repeated 
measures ANOVA indicated an effect of time (F(9,351)= 5.6, P < 0.001), a time x 
dose interaction (F(36,251)= 1.8, P < 0.01) and an effect of dose (F(4,39)= 13.7, P 
< 0.001). Cortical 5-HT levels were reduced by CP93129 in the presence of 
fluvoxamine at concentrations of 3 µM and 10 µM to a minimum of 72 ± 6.3 % and 
59 ± 3.8% of basal levels, respectively. The effect of CP93129 (0.1 µM) was 
significantly greater in the absence of fluvoxamine as compared to the effects of 
CP9319 in the presence of 3 µM or 10 µM fluvoxamine (F(1,14)= 9.4, P < 0.01 
and F(1,10)= 6.0, P < 0.05, respectively). There was no difference between the 
effects of CP93129 at 3 or 10 µM fluvoxamine. At a higher concentration of 
fluvoxamine (30 µM), CP93129 did not affect cortical 5-HT levels.  
 
 
Effects of 5-HT1B receptor antagonists on extracellular 5-HT 
In the absence of fluvoxamine, local administration of all three 5-HT1B receptor 
antagonist alone reduced 5-HT levels (Fig.2A). When compared to vehicle, 5-HT  
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Fig.2. Time course of the effects 5-HT1B receptor antagonists on extracellular 5-HT in
the frontal cortex. Data are expressed as mean percentage change from basal 5-HT
levels ± SEM. Locally administration of 10 µM GR127935, 1 µM SB224289 or 1 µM
NAS-181, as indicated by the bar, either in the absence (A) or presence of 3 µM
fluvoxamine (B). See Results for details on statistical analysis. 
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Fig.1. Time course of the effects of the 5-HT1B receptor agonist CP93129 on 
extracellular 5-HT in the frontal cortex. Data are expressed as mean percentage change
from basal 5-HT levels ± SEM. CP93129 was administered locally into the frontal cortex
for 45 minutes as indicated by the bar. CP93129 was administered at concentrations of
0.03, 0.1 and 0.3 µM (A) in the absence of a SSRI. CP93129 (0.1 µM) at concentrations 
of 3, 10 or 30 µM fluvoxamine (B). See Results for details on statistical analysis. 
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levels were significantly reduced by perfusion with 10 µM GR127935 (F(1,15)= 
11.9, P < 0.05), 1 µM SB22428 (F(1,18)= 4.8, P < 0.05) and 1 µM NAS-181 
(F(1,13)= 6.9 , P < 0.05). 
In the presence of 3 µM fluvoxamine, the suppressant effects of NAS-181 and 
SB224289 were absent, although GR217935 slightly reduced 5-HT levels 
(Fig.2B). Administration of GR127935 alone in the presence of fluvoxamine 
slightly, but significantly reduced 5-HT levels as compared to vehicle (F(1,12)= 
7.9, P < 0.05). Administration of SB224289 alone, slightly increased 5-HT 
levels, but this effect was not significantly different from vehicle (F(1,13)= 2.5, 
P = 0.14 ). Administration of NAS-181 alone did not affect 5-HT levels in the 
presence of fluvoxamine. 
 
Effects of 5-HT1B receptor antagonists on the effect of CP93129 
In the absence of fluvoxamine, the suppressant effect of CP93129 (0.1 µM) on 5-
HT output was attenuated by co-perfusion with NAS-181 and GR127935, but not 
with SB224289 (Fig.3A,C,E). For the effects of GR127935, an effect of time 
(F(9,252)= 8.6, P < 0.001), a time x treatment interaction (F(27,252) 2.7, P < 
0.001) and an effect of treatment (F(3,28)= 15.1, P < 0.001) was found. As shown 
in Fig.3A, co-perfusion with GR127935 attenuated the effect of CP93129 as 
indicated by a significant time x treatment interaction (F(9,108)= 7.3, P < 0.001). 
For the effects of SB224289, an effect of time (F(9,252)= 8.6, P < 0.001), a time x 
treatment interaction (F(27,252)= 2.7, P < 0.001) and an effect of treatment 
(F(3,28)= 15.1, P < 0.001) was found. As shown in Fig.3C, co-perfusion with 
SB224289 did not attenuate the effect of CP93129 (F(1,11)= 2.2, P = 0.16). For 
the effects of NAS-181, an effect of time (F(9,207)= 9.3, P < 0.001), a time x 
treatment interaction (F(27,207)= 3.0, P < 0.001) and an effect of treatment 
(F(3,23)= 11.5, P < 0.001) was found. As shown in Fig.3E, co-perfusion with NAS-
181 significantly attenuated the effect of CP93129 (F(1,10)= 9.0, P < 0.05).  
In the presence of 3 µM fluvoxamine, the suppressant effect of CP93129 on 5-HT 
levelswas attenuated by co-perfusion with NAS-181 and GR127935, but not with 
SB224289 (Fig.3B,D,F). For the effects of GR127935, an effect of a time x 
treatment interaction (F(27,207)= 3.1, P < 0.001) and of treatment (F(3,23)= 6.7, P 
< 0.05) was seen. As shown in Fig.3A, co-perfusion with 10 µM GR127935 
blocked the effect of CP93129 as indicated by a significant time x treatment 
interaction (F(9,99)= 2.0, P < 0.001). For the effects of SB224289, an effect of 
time (F(9,225)= 2.2, P < 0.05), a time x treatment interaction (F(27,225)= 2.0, P < 
0.01) and of treatment (F(3,25)= 10.3, P < 0.001) was found. Co-perfusion with 1 
µM SB224289 in the presence of fluvoxamine did not attenuate the suppressant 
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effect of CP93129 on 5-HT levels (Fig.3D). For the effects of NAS-181, an effect 
of time (F(9,252)= 2.9, P < 0.01), a time x treatment interaction (F(27,252)= 2.8, P 
< 0.001) and an effect of treatment (F(3,28)= 4.4, P < 0.05) was found. As shown 
in Fig.3F, co-perfusion with 1 µM NAS-181 significantly blocked the effect of 
CP93129  (F(1,13)= 9.3, P < 0.01).  
 
 
 
Discussion 
 
The main finding of the present study is that NAS-181, a new selective 5-HT1B 
receptor antagonist, blocked the suppressant effect of CP93129 on cortical 5-HT 
levels. Stimulation of 5-HT1B receptors with CP93129 dose-dependently reduced 
5-HT levels in the frontal cortex. The maximum suppressant effect of CP93129 
(0.1 µM) on 5-HT levels was reduced in the presence of a SSRI in the perfusion 
fluid. Both in the presence and absence of fluvoxamine, the suppressant effect of 
CP93129 on 5-HT was attenuated by NAS-181 (1 µM) and GR127935 (10 µM), 
but not by SB224289 (1 µM). In the absence of fluvoxamine, all three antagonists 
showed agonistic properties and significantly reduced cortical 5-HT levels.  
The effects of CP93129 confirm findings from previous microdialysis studies 
demonstrating that activation of 5-HT1B autoreceptors reduce 5-HT levels in rat 
frontal cortex (Hertel et al., 1999, Adell et al., 2001). The suppressant effect of 
CP93129 (0.1 µM) on 5-HT levels was reduced when fluvoxamine (3 or 10 µM) 
was added to the perfusion fluid. At higher concentrations of fluvoxamine (30 µM) 
the effect of CP3129 on 5-HT levels was absent. A possible explanation for this 
finding may be that the effect of CP93129 is limited due to competition at 5-HT1B 
autoreceptor sites by increasing endogenous 5-HT levels dose-dependently 
induced by fluvoxamine. Previous studies have shown that locally applied SSRIs 
 
 
 
 
 
 
 
Fig.3. (next page). Time course of the effects of 5-HT1B receptor antagonists on the
suppressant effect of CP93129 on 5-HT levels. Data are expressed as mean percentage
change from basal 5-HT levels ± SEM. The 5-HT1B receptor agonist CP93129 (0.1 µM)
was locally administered into the frontal ortex for 45 minutes as indicated by the black bar
either in the absence (left panel) or presence of 3 µM fluvoxamine (right panel).
Administration of the 5-HT1B receptor antagonists 10 µM GR127935 (A-B), 1 µM
SB224289 (C-D) and 1 µM NAS-181 (E-F), indicated by the white bars, started 15
minutes before the agonist was co-perfused and lasted until the end of the sampling
period. See Results for details on statistical analysis. 
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into the frontal cortex dose-dependently increase 5-HT levels up to 5-10 fold 
following high concentrations of the SSRI citalopram (Hervas et al., 2000, Tao et 
al., 2000), while in the present study 3 µM fluvoxamine increased cortical 5-HT 
levels about two-fold. At this concentration 5-HT reuptake sites are presumably 
not maximally blocked.  
Surprisingly, in the absence of a SSRI in the perfusion fluid, 10 µM GR127935, 1 
µM SB224289 and 1 µM NAS-181 reduced cortical 5-HT levels, suggesting partial 
agonistic properties of these receptor antagonists. GR127935 and SB224289 are 
compounds that have been used in many studies as 5-HT1B receptor antagonists, 
although there is some evidence to suggest that these compounds are not silent 
receptor antagonists. GR127935 has been found to display partial and inverse 
agonistic properties at human 5-HT1B receptors in vitro (Walsh et al., 1995, 
Pauwels, 1997). Moreover, GR127935 has been found to behave as a partial 
agonist at rodent 5-HT1B receptors expressed in an opossum kidney cell line 
(Zgombick and Branchek, 1998).  Also SB22429 has been found to display 
inverse agonist properties at human 5-HT1B receptors, although there is thus far 
no evidence for such properties in vivo (Millan et al., 1999). Systemic 
administration of GR127935, but not of SB224289, has been reported to decrease 
5-HT levels in the frontal cortex of guinea pigs, but this effect was attributed to the 
involvement of 5-HT1B/1D receptors in the raphe nucleus (Roberts et al., 1999). 
Locally applied GR127935 (10 µM) into guinea pig cortex has been reported to 
slightly increase 5-HT levels, but this effect was not significantly different from 
vehicle (Hutson et al., 1995). In a previous study, NAS-181 administered 
systemically or locally (10 µM) had no effect on 5-HT levels in rat frontal cortex 
(Hjorth et al., 2000). In contrast, our findings show that 1 µM NAS-181 may act as 
a partial agonist at 5-HT1B autoreceptors.  Although we used a lower concentration 
of NAS-181, it is unlikely that this discrepancy can be attributed to the difference 
in concentration. 
In the present study we chose a sub-maximal concentration of fluvoxamine to 
determine the potency of the three 5-HT1B receptor antagonists to block the 
suppressant effect of CP93129 on cortical 5-HT levels. Co-perfusion of 3 µM 
fluvoxamine with 1 µM NAS-181 or 1 µM SB224289 had no effect on cortical 5-HT 
levels, whereas 10 µM GR127935 slightly reduced 5-HT levels. In previous 
studies, it was reported that 10 µM GR127935 did not affect 5-HT levels, whereas 
a tenfold higher concentration increased cortical 5-HT in the presence of the SSRI 
citalopram (1 µM) (Hervas et al., 1998, Hertel et al., 1999). In the presence of 
citalopram, SB224289 (1-100 µM) locally applied into the raphe nuclei had no 
effect on 5-HT levels  (Adell et al., 2001). NAS-181 at a concentration of 10 µM 
was found to increase 5-HT levels in rat frontal cortex in the presence of 
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citalopram (Hjorth et al., 2000). In the present study, we choose a 10-fold lower 
concentration of NAS-181 because this concentration had no effect on 5-HT levels 
when co-perfused with fluvoxamine. 
It has been suggested that the effect of an antagonist at the 5-HT1B autoreceptor 
is dependent on the endogenous tone at 5-HT1B binding sites, which is low at 
basal conditions (Hjorth, 1993). In the present study NAS-181 and GR127935 
attenuated the effect of CP93129 both in the absence and presence of a sub-
maximal concentration of locally applied fluvoxamine. The present finding that 
these receptor antagonists act as partial agonists when administered alone, but 
display antagonistic properties when the endogenous tone is enhanced by local 
fluvoxamine would fit with the notion that the effect of a 5-HT1B receptor antagonist 
depends the endogenous tone of this receptor. Also following stimulation of 5-
HT1B receptors by an exogenous applied agonist, the endogenous tone at 5-HT1B 
sites will be raised. Therefore, in combination with a full agonist, a partial agonist 
may act as an antagonist. Indeed, co-perfusion of GR127935 and NAS-181 
significantly attenuated the effect of the full 5-HT1B receptor agonist CP93129 in 
the absence of fluvoxamine. The effect of CP93129 was not attenuated by 
SB224289, possibly, the concentration used of this receptor antagonist was not 
sufficient to block 5-HT1B sites.  
In conclusion, the antagonistic properties of NAS-181 in blocking the suppressant 
effect of locally applied CP93129 on 5-HT levels show that NAS-181 is a potent 5-
HT1B receptor antagonist. Co-perfusion of NAS-181 or GR127935, but not of 
SB224289, attenuated the suppressant effect CP93129, both in the presence and 
absence of fluvoxamine. The reduced 5-HT levels following local administration of 
GR127935, SB224289 or NAS-181 suggests that these compounds may have 
partial agonistic properties. 
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Abstract 
 
The release of serotonin (5-HT) at serotonergic nerve terminals is regulated by 5-
HT1B autoreceptors. Several studies have reported that the effects of selective 5-
HT reuptake inhibitors (SSRIs) on extracellular 5-HT are augmented by 5-HT1B 
receptor antagonists, whereas administration of these antagonists alone do not 
enhance 5-HT levels. It has been suggested that 5-HT1B receptors have low basal 
endogenous activity and therefore elevated endogenous 5-HT levels are needed 
to elicit an effect of 5-HT1B receptor antagonists. To test this hypothesis, different 
strategies were used to enhance 5-HT levels in rat frontal cortex to assess the 
effects of locally applied NAS-181, a new selective 5-HT1B receptor antagonist.  
Blockade of 5-HT1B receptors with NAS-181 dose-dependently augmented 5-HT 
levels when 5-HT levels were enhanced by a SSRI. No additional effect of NAS-
181 on 5-HT output was found when 5-HT levels were enhanced by KCl 
depolarization induced release or by preventing degradation of 5-HT with the 
mono-oxidase inhibitor pargyline. In the presence of fluvoxamine, the increased 5-
HT release evoked by KCl depolarization was augmented by NAS-181, supporting 
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the idea that blockade of 5-HT transporters is necessary to measure an effect of 
5-HT1B receptor blockade. In conclusion, the results provide circumstantial 
evidence that the effect of a 5-HT1B receptor antagonist depends on extracellular 
5-HT levels, but strongly suggest that additional 5-HT reuptake inhibition is 
required to detect any effect of 5-HT1B receptor antagonist on 5-HT levels by in 
vivo microdialysis. 
 
 
Introduction 
 
Selective 5-HT reuptake inhibitors (SSRIs) are widely used in the treatment of 
depression and anxiety disorders. However, several weeks of SSRI-treatment are 
needed before a therapeutic effect is achieved, suggesting that adaptive changes 
might be implicated. SSRIs inhibit the reuptake of 5-HT, thereby enhancing 5-HT 
levels. The release of 5-HT in the CNS is controlled by 5-HT1A and 5-HT1B 
autoreceptors. At serotonergic nerve terminals 5-HT release is regulated by 5-
HT1B autoreceptors (Engel et al., 1986, Maura et al., 1986).  In vivo microdialysis 
studies have shown that stimulation of 5-HT1B receptors inhibits the release of 5-
HT in different brain areas (Hjorth and Tao, 1991, Bosker et al., 1995, Adell et al., 
2001). Terminal 5-HT1B receptors have been found to desensitize after chronic 
administration of antidepressants in different brain areas, including the frontal 
cortex (Blier et al., 1984, Moret and Briley, 1990, O'Connor and Kruk, 1994, el 
Mansari et al., 1995, Newman et al., 2000). It has been suggested, therefore, that 
the therapeutic effect of SSRIs could be accelerated by concurrent administration 
of a 5-HT autoreceptor antagonist. There is some clinical evidence that pindolol, a 
ß-adrenoceptor and 5-HT1A receptor antagonist, may have a beneficial effect on 
SSRI-treatment (Artigas et al., 2001). In this view, also the 5-HT1B autoreceptor 
may be a target for augmentation strategies of SSRI-treatment. Whereas 
stimulation of 5-HT1B receptors results in reduced 5-HT levels, blockade of 5-HT1B 
receptors in general has no effect on 5-HT levels (Roberts et al., 1998, Hjorth et 
al., 2000, Gobert et al., 2000). The effect of systemic SSRIs on 5-HT levels are 
augmented by 5-HT1B receptor antagonists in the frontal cortex (Gobert et al., 
1997 Dawson and Nguyen, 2000, Gobert et al., 2000) and other brain areas 
(Rollema et al., 1996, Cremers et al., 2000). Compounds that act both as a SSRI 
and 5-HT1B receptor antagonist have been found to potently enhance 5-HT levels 
(Matzen et al., 2000, Mitchell 2001). Furthermore, a limiting role of 5-HT1B 
autoreceptors in the effect of SSRIs on cortical 5-HT levels is supported by recent 
findings in mice lacking 5-HT1B receptors (Malagie et al., 2001, de Groote et al., 
2002b). It has been suggested that 5-HT1B receptors have low basal endogenous 
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activity. This notion is based on findings that the effect of 5-HT1B receptor 
blockade was not measurable when a SSRI was omitted from the perfusion fluid 
(Hjorth, 1993), suggesting that stimulation of 5-HT1B receptors, i.e. through 
elevated 5-HT levels resulting from 5-HT reuptake inhibition, is required for 5-HT1B 
receptor antagonists to affect extracellular 5-HT levels.  
In the present study, NAS-181, a new selective rodent 5-HT1B receptor antagonist 
was used to block 5-HT1B receptors (Berg et al., 1998, Stenfors et al., 2000). The 
aim of the present study was to investigate whether the effects of terminal 5-HT 
autoreceptor blockade depends on the endogenous tone at 5-HT1B autoreceptors. 
To test this hypothesis, different strategies were used to enhance 5-HT levels in 
rat frontal cortex to assess the effects of locally applied NAS-181.  First, 5-HT 
levels were enhanced by the 5-HT reuptake inhibitor fluvoxamine administered 
locally by reversed microdialysis. Second, 5-HT levels were enhanced by local 
potassium chloride stimulation and third by local administration of pargyline, a 
mono-oxidase inhibitor through the microdialysis probe, to block 5-HT 
degradation. 
 
 
Material and methods 
 
Animals  
Male Wistar rats (GDL, Utrecht, The Netherlands) weighing 250-300 gram were 
housed three per cage under standard conditions (22-24 ºC), food and water ad 
lib) and a 12-hour light/dark cycle (7 a.m. on, 7 p.m. off). The Ethical Committee 
for Animal Research of the University Medical Center Utrecht, The Netherlands, 
approved the study. 
 
Microdialysis procedure  
Rats were anaesthetized with chloral hydrate (400 mg/kg i.p.). A self-constructed 
concentric microdialysis probe with an AN 69 Filtral membrane (Hospal, Uden, the 
Netherlands) was stereotaxically implanted in the frontal cortex. The probe was 
positioned in the frontal cortex using the following coordinates: AP + 3.7, ML –2.6 
and DV –5.5 mm from bregma (Paxinos and Watson, 1982). The active dialysis 
surface length of the probes was 2 mm (outer diameter 310 µM). The probes were 
secured in place with dental cement. Microdialysis experiments started 16-20 
hours after surgery, about two hours after lights were on. Probes were perfused 
with Ringer solution (147 mM NaCl, 2.3 mM KCl,  2.3 mM CaCl2, 1.0 mM MgCl2) 
at a constant flow of 1.5 µl/min with a high precision pump (Harvard Scientific, 
USA). Probes were connected with PE-tubing to swivels (Instech Laboratories, 
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USA) to allow unrestrained movements of the rats. After the start of the dialysis 
perfusion, animals were left undisturbed for two hours before collection of samples 
started. Samples were collected every 15 minutes in vials containing 7.5 µl acetic 
acid. Until HPLC analysis, samples were stored at –80°C. At the end of the 
experiment the rats were deeply anaesthetized with chloral hydrate. After 
decapitation, brains were removed and fixed in 4% formaldehyde solution. To 
verify the position of the probe the brains were cut in 50 µm slices on a vibratome. 
In case of improper probe placement, data was excluded. 
 
HPLC-ECD analysis  
5-HT was analyzed by HPLC with electrochemical detection. Samples were 
injected onto an Inertsil ODS-3 column (3 µM, 2.1x100mm, Aurora Borealis,The 
Netherlands) using a Gilson pump and autosampler (Separations, The 
Netherlands). Separation was performed at 40ºC with the electrochemical detector 
(Intro, ANTEC Leyden, The Netherlands) set at a potential of 600 mV against an 
Ag/AgCl reference electrode. The signal was analyzed using Gynkotek software. 
The mobile phase consisted of 5 g/l (NH4)2SO4, 150 mg/l heptane sulphonic acid 
sodium salt, 0.5 g/l EDTA, 5% methanol, 30 µl/l triethylamine, 30 µl/l acetic acid, 
pH 4.6. Flow rate was 0.3 ml/min. The detection limit for 5-HT was 0.5 fmol/25 µl 
sample (signal to noise ratio 2). 
 
Drugs 
The following drugs were used; fluvoxamine maleate (donated by Solvay 
Pharmaceuticals, The Netherlands), NAS-181 ((R)-(+)-2-[[[3-(Morpholinomethyl)-
2H-chromen-8-yl]oxy]methyl] morpholine methane sulfonate) (donated by 
AstraZeneca, Sweden) and pargyline (Sigma, USA). All drugs were applied locally 
through the probe by reversed microdialysis. Drugs were first dissolved in distilled 
water and further diluted in Ringer solution on the day of the experiment. For the 
fluvoxamine groups, the SSRI was present in the Ringer solution from the start of 
dialysis. All other chemicals and reagents were of the purest commercially 
available. 
 
Data analysis and statistics 
Values for the first four consecutive samples were averaged to calculate the basal 
levels of extracellular 5-HT, uncorrected for probe recovery. In the figures, all 5-
HT values are expressed as percentages of basal levels ± SEM. Effects of 5-HT 
response to drug treatment were analyzed by multivariate analysis of variance 
(ANOVA) for repeated measurements with time as ‘within’ and treatment (or dose) 
as ‘between’ factors. When appropriate, data were broken down on treatment (or 
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dose) and pairwise comparisons were made of the time profiles between the 
treatment groups (or dose effects). The significance level for all analyses was set 
at 5%. In the figures showing time course, the start of local infusion (time point 
zero) of drugs is corrected for the dead volume of the microdialysis system. 
 
 
Results 
 
Effects of NAS-181 in the presence of a SSRI 
As shown in Fig.1, cortical 5-HT levels were enhanced by NAS-181 in the 
presence of the SSRI fluvoxamine. The effects of two concentrations NAS-181 
were assessed in the absence and presence of fluvoxamine at two 
concentrations. 
In the absence of fluvoxamine, an effect of time (F(9,153)= 3.3, p < 0.001) and a 
time x dose interaction (F(18,171)= 4.2, p = 0.01), but no dose effect (F(2,17)= 
2.0, p = 0.078) was found. Cortical 5-HT levels were reduced by 1 µM NAS-181 
as compared to baseline (F(1,14)= 5.4, p < 0.05). A tenfold higher concentration 
of NAS-181 did not affect 5-HT levels. 
In the presence of 3 µM fluvoxamine, an effect of time (F(9,207)= 2.3, p < 0.001) 
and a dose effect (F(1,23)= 19.2, p < 0.001) was seen. Cortical 5-HT levels were 
not augmented by 1 µM NAS-181, whereas 10 µM NAS-181 increased 5-HT 
levels of baseline (F(1,16)= 24.9, p < 0.001). One hour after the co-perfusion with 
NAS-181 started the mean  maximum increase of 5-HT amounted to 139 ± 12 %. 
In the presence of 10 µM fluvoxamine, a repeated measures ANOVA indicated an 
effect of time (F(9,171)= 7.1, p < 0.001), a time x dose interaction (F(18,171)= 4.2, 
p <0.001) and a dose effect (F(2,19)= 9.6, p < 0.001). Cortical 5-HT levels were 
not augmented by 1 µM NAS-181, whereas 10 µM NAS-181 increased 5-HT 
levels from baseline (F(1,14)= 14.0, p < 0.01). The mean maximum increase of 5-
HT amounted to 184 ± 34 % of baseline levels after one hour of co-perfusion with 
NAS-181. No statistical difference was found between the effect of NAS-181 at 3 
or 10 µM fluvoxamine (F(1,13)= 0.99, p = 0.34). 
 
Effects of NAS-181 in the absence of a SSRI  
Fig.2. shows the effects of NAS-181 using two other strategies to enhance 5-HT 
levels without blocking 5-HT reuptake. Cortical 5-HT levels were increased by 
stimulation of 5-HT release with potassium chloride (KCl) (Fig.2A). A repeated 
measures ANOVA indicated an effect of time (F(9,189)= 17.5, p < 0.001), a time x 
treatment interaction (F(27,189)= 7.3, p <0.001) and a treatment effect (F(3,21)=  
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Fig.1. Effects extracellular 5-HT of the 5-HT1B receptor antagonist NAS-181 in the 
absence and presence of a SSRI. Data are expressed as mean change in 5-HT levels 
from basal ± SEM. Perfusion of NAS-181 (1 µM) started at time point zero indicated by 
the open bar, either in the absence of fluvoxamine (A), at 3 µM (B) or at 10 µM 
fluvoxamine (C). Fluvoxamine was present in the perfusion fluid from the start of the
dialysis. See text Results for details on statistical analysis. 
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4.4, p < 0.05). Following 15 minutes of 120 mM  KCl, cortical 5-HT levels were 
increased to a mean maximum increase to 334 ± 103 % from baseline (F(1,14)= 
8.3, p < 0.05). Co-perfusion with 10 µM NAS-181 did not affect the 5-HT release 
evoked by KCl depolarization (F(1,8)= 0.5, p = 0.5). Local administration of 
pargyline, a mono-oxidase inhibitor, increased 5-HT levels significantly (Fig.2B). 
Statistical analysis revealed an effect of time (F(9,198)= 27.3, p < 0.001), a time x 
treatment interaction (F(27,198)= 10.9, p <0.001) and a treatment effect (F(3,22)= 
11.2, p < 0.001). 
Local perfusion of 500 µM pargyline increased cortical extracellular 5-HT levels to 
237 ± 31 % of baseline following 2 hours of perfusion (F (1,14)= 18.1, p < 0.001). 
Co-perfusion with 10 µM NAS-181 had no additional effect on the pargyline- 
induced 5-HT increase ( F(1,10)= 0.09, p = 0.77). 
 
Fig.2. Effects of NAS-181 with enhanced 5-HT levels in the absence of a SSRI. Data
are expressed as mean change in 5-HT levels from basal ± SEM. Local administration
of 10 µM NAS-181 started at timepoint zero as indicated by the white bar. Stimulation of
5-HT release by 120 mM KCl (black bar) for 15 minutes (A). Local administration of 500
µM pargyline (hatched bar) started 30 minutes after perfusion with NAS-181 (B). See
text Results for details on statistical analysis. 
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Effects of NAS-181 on KCl-evoked 5-HT release in the presence of 
fluvoxamine 
Fig.3 shows the effects of NAS-181 on KCl depolarization induced 5-HT release in 
the presence of 3 µM fluvoxamine. A repeated measures ANOVA indicated an 
effect of time (F(9,225)= 7.2, p < 0.001), a time x treatment interaction (F(27,225)= 
3.4, p <0.001) and a treatment effect (F(3,25)= 16.9, p < 0.001). Stimulation with 
60 mM KCl in the presence of 3 µM fluvoxamine increased 5-HT to 134  ± 10 % of 
baseline (F(1,14)= 5.0, p < 0.05). Co-perfusion of 10 µM NAS-181 with 3 µM 
fluvoxamine enhanced 5-HT levels to the same extent. Co-administration with 10 
µM NAS-181 augmented the effect of KCl-evoked 5-HT release to a mean 
maximum of 208 ± 28 % of baseline (F(1,9)= 15.6, p < 0.01).   
 
 
Discussion 
 
The main finding of the present study is that blockade of 5-HT1B receptors with 
NAS-181 augmented dose-dependently 5-HT levels in the presence of a SSRI. 
Local KCl depolarization or pargyline administration enhanced cortical 5-HT 
levels, but no effect of NAS-181 was found. Whereas, in the presence of 
fluvoxamine the effect of KCl depolarization induced release of 5-HT was 
augmented by NAS-181.  
Fig.3. Effects of NAS-181 on KCl 
depolarization induced 5-HT release 
in the presence of a SSRI. Data are 
expressed as mean change in 5-HT 
levels from basal ± SEM. Stimulation 
of 5-HT release by 60 mM KCl for 15 
minutes (black bar) in the presence 
of 3 µM fluvoxamine. Administration 
or co-administration of 10 µM NAS-
181 (white bar) started 15 minutes 
before KCl stimulation. See text 
Results for details on statistical 
analysis. 
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It has been suggested that the basal endogenous tone at 5-HT1B receptors is low 
(Hjorth, 1993). This may explain why extracellular 5-HT levels are not affected by 
local administration of 5-HT1B receptor antagonists alone, whereas at elevated 
extracellular 5-HT levels induced by co-perfusion with a SSRI, blockade of 5-HT1B 
receptors augments extracellular 5-HT. The present study confirms that 5-HT1B 
receptor antagonists enhance 5-HT levels, as NAS-181 at a concentration of 10 
µM augmented 5-HT levels at two different concentrations of fluvoxamine. These 
findings are in line with previous studies in rat frontal cortex using locally applied 
5-HT1B receptor antagonist in the presence of a SSRI in the perfusion fluid (Hertel 
et al., 1999, Hjorth et al., 2000). A lower concentration of NAS-181 (1µM) did not 
affect extracellular 5-HT levels in the presence of fluvoxamine, and reduced 
extracellular 5-HT levels in the absence of fluvoxamine, suggesting partial 
agonistic properties of this compound. In combination with a full agonist, a 
combined partial agonist may act as an antagonist. Indeed, co-perfusion of 1 µM 
NAS-181 attenuated the effect of the full 5-HT1B receptor agonist CP93129 
(chapter 5). The discrepancy in the present findings that NAS-181 displayed 
partial agonistic properties at a concentration of 1 µM, but not at the 10-fold higher 
concentration is unclear.  
To study whether the role of SSRIs in the effect of 5-HT1B receptor antagonists 
was due to the extracellular 5-HT concentrations or related to the properties of 
SSRIs, the effects of NAS-181 were studied using two other strategies aimed to 
enhance extracellular 5-HT levels. Local administration of pargyline gradually 
increased 5-HT levels, but co-perfusion with NAS-181 did not augment the effect 
of pargyline. Stimulation with 120 mM KCl evoked a fast increase in 5-HT levels, 
but co-perfusion with NAS-181 had no additional effect. Both pargyline and KCl 
depolarization are non-selective in that they increase extracellular levels of other 
neurotransmitters as well. Moreover, no steady-state 5-HT levels were obtained 
with either approach. The effects on extracellular 5-HT following KCl were only 
transient and 5-HT levels following pargyline were still rising 2 h after the 
administration started, which may have obliterated any effect of NAS-181 on 5-HT 
release. A study in mice, however, showed that the 5-HT1B receptor agonist 
CP93129 was able to attenuate the KCl-evoked release of 5-HT in the frontal 
cortex of wildtype mice, and this effect was absent in 5-HT1B receptor knockout 
mice (Trillat et al., 1997). Interestingly, in the presence of fluvoxamine, the evoked 
5-HT increase induced by 60 mM KCl could be augmented by NAS-181. This may 
suggest that the effect of NAS-181 depends on the presence of a SSRI. There is 
circumstantial evidence to suggest that a functional interaction exist between the 
5-HT1B autoreceptor and the 5-HT transporter. Daws et al (1999) have 
hypothesized that the activation of 5-HT1B receptors may enhance the activity of 5-
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HT transporters resulting in a greater clearance of 5-HT from the synaptic cleft. 
This was supported by findings showing that the clearance of 5-HT in the 
hippocampus, as measured with in vivo voltammetry, was inhibited by different 5-
HT1B receptor antagonists (Daws et al., 1999). Moreover, the inhibitory effect on 5-
HT clearance of a 5-HT1B receptor antagonist co-administered with a SSRI 
appeared to be additive (Daws et al., 2000). Nevertheless, there may be a 
important difference in methodology between in vivo microdialysis and 
voltammetry. With the latter technique, 5-HT1B receptors antagonists are found to 
inhibit the clearance of 5-HT, which is expected to result in enhanced extracellular 
5-HT levels, but in most microdialysis studies no effects on extracellular 5-HT 
levels are found. An explanation for these discrepant findings for 5-HT1B receptor 
antagonists on extracellular 5-HT levels in the absence of a SSRI might be that by 
5-HT levels, as measured by in vivo microdialysis, do not detect actual release of 
5-HT at the site of release. When the release of 5-HT is increased by blockade of 
inhibitory 5-HT1B receptors, this increase in 5-HT may be not detected at the site 
of the probe as it is rapidly removed from the extracellular space before it can 
reach the microdialysis probe. The re-uptake of 5-HT is prevented by a SSRI, 
resulting in measurable increases in 5-HT levels in the sampled dialysates.  
In conclusion, blockade of 5-HT1B receptors with the selective 5-HT1B receptor 
antagonist NAS-181 dose-dependently augmented 5-HT levels when 5-HT levels 
were enhanced by a SSRI. No additional effect of NAS-181 on 5-HT output was 
found when 5-HT levels were enhanced by KCl depolarization induced release or 
by blockade of 5-HT degradation with the mono-oxidase inhibitor pargyline in the 
absence of a SSRI. The increase in 5-HT release evoked by KCl depolarization 
was augmented by NAS-181 in the presence of fluvoxamine, supporting the idea 
that the effect of 5-HT1B receptors blockade is dependent on the extracellular 5-HT 
levels. The results provide circumstantial evidence that the effect of a 5-HT1B 
receptor antagonist depends on extracellular 5-HT levels, but also strongly 
suggest that 5-HT reuptake inhibition is necessary to measure the effects by 
means of in vivo microdialysis.  
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General discussion 
  
Functional role of 5-HT1B receptors 
5-HT1B autoreceptors  
5-HT1B heteroreceptors 
 
Knockout mouse versus pharmacological tools 
  5-HT1B receptor ligands 
  Compensatory changes in 5-HT1B knockout mice 
  The 5-HT1B knockout mouse as model to study 5-HT1B receptors 
 
Methodological considerations on microdialysis 
Extracellular 5-HT 
  Regulation of 5-HT in mouse and rat 
 
Future directions 
 
 
 
 
The aim of this thesis was to explore the role of 5-HT1B receptors in 5-HT 
function, which was studied by in vivo microdialysis in mice and rats. The first part 
of the thesis describes the role of 5-HT1B receptors on extracellular 5-HT levels by 
comparing the effects of SSRIs between wildtype and 5-HT1B receptor knockout 
mice in different brain areas. Furthermore a study was undertaken to assess the 
role of 5-HT1B heteroreceptors on DA outflow in the striatum. In the second part of 
this thesis, the effect of a new selective receptor antagonist on extracellular 5-HT 
was evaluated in the frontal cortex of rats. This chapter discusses the functional 
role of 5-HT1B auto- and heteroreceptors. The chapter is concluded with 
comments on the use of knockout mice and pharmacological tools to study 5-HT1B 
receptor function in rodents and suggestions for future research directions are 
given. 
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Functional role of 5-HT1B receptors 
 
5-HT1B autoreceptors 
To validate the microdialysis procedure in mice, we first aimed to replicate 
previously reported findings. Therefore, a SSRI was administered systemically 
and extracellular 5-HT levels were assessed in the hippocampus of wildtype and 
5-HT1B knockout mice (chapter 2). The 5-HT response to the SSRI paroxetine was 
augmented in 5-HT1B KO mice and this finding is in line with previously reported 
results (Malagie et al., 2001). Following systemic SSRI-administration, also 5-
HT1A, 5-HT1D, and 5-HT1B autoreceptors localised in the raphe nuclei may affect 
the output of 5-HT in serotonergic projection areas. Therefore, the role of 5-HT1B 
autoreceptors in the effects of SSRIs on extracellular 5-HT was assessed by local 
administration of the SSRI fluvoxamine into different brain areas. In 5-HT1B 
knockout mice relative to wildtypes, 5-HT levels were increased following locally 
applied fluvoxamine into the hippocampus and the medial prefrontal cortex, but 
not in the striatum (chapters 2,3,4). In the frontal cortex, the 5-HT1B receptor 
antagonist NAS-181 augmented the effect of locally applied fluvoxamine in mouse 
(chapter 3) and rat (chapter 6). The effects of a locally applied SSRI indicate that 
terminal 5-HT1B receptors are functionally involved in the regulation of 5-HT when 
5-HT levels are enhanced. In the striatum of wildtype mice, stimulation of 5-HT1B 
receptors reduced extracellular 5-HT, indicating that 5-HT1B receptors are 
functionally present in this brain structure. In line with our findings, a previous 
study using systemic injection of a SSRI, found no differences between the two 
genotypes in the striatum (Knobelman et al., 2001a). Interestingly, after chronic 
SSRI-treatment increased 5-HT1B mRNA levels were observed in the striatum, 
suggesting that adaptive changes in 5-HT1B heteroreceptors in this brain area may 
be implicated in the chronic effects of antidepressants (Le Poul et al., 2000). 
Taken together, the present findings in rat, wildtype and 5-HT1B knockout mice, 
clearly indicate that 5-HT1B autoreceptors at serotonergic nerve terminals limit the 
acute effects of SSRIs in the hippocampus and prefrontal cortex, but not in the 
striatum.  
 
5-HT1B heteroreceptors 
In contrast to the well-established inhibitory role of 5-HT1B autoreceptors in 5-HT 
release, relatively little is known about the functional role of 5-HT1B 
heteroreceptors. The previously reported role of striatal 5-HT1B heteroreceptors in 
DA outflow in the striatum could not be confirmed in our study (chapter 4), since 
the effect of the putative selective 5-HT1B receptor agonist CP93129 on DA 
outflow was similar in the two genotypes, demonstrating that 5-HT1B receptors 
General discussion | 83 
were not involved. This finding does not exclude an effect of 5-HT1B 
heteroreceptors on DA outflow in the striatum. Enriched 5-HT1B binding sites are 
found in the basal ganglia and particularly in the substantia nigra (SN). 5-HT1B 
receptors are present as presynaptic heteroreceptors on GABA-ergic neurons 
projecting from the striatum to the SN (Boschert et al., 1994, Stanford and Lacey, 
1996). Ultrastructural analysis of the SN pars reticulata (SNr) demonstrated that 
almost all 5-HT varicosities are of the junctional type, while in other brain areas 
predominantly non-junctional varicosities are found (Moukhles et al., 1997). The 
precisely organised 5-HT input to the SNr suggests that 5-HT can finetune the 
motor output of the basal ganglia by acting on the GABA projections either directly 
or through modulation of local release of dopamine by dopaminergic dendrites. 
Moreover, a role of 5-HT1B receptors in locomotor behaviour is supported by 
findings in 5-HT1B knockout mice showing that the hyperlocomotor effect of the 5-
HT 1A/1B agonist RU24969 is absent (Saudou et al., 1994). Furthermore, local 
administration of a 5-HT 1B/1D receptor agonist into the SN induced contralateral 
turning behaviour in guinea pig and rat (see Barnes and Sharp, 1999). 
Interestingly, reduced 5-HT1B bindings sites were observed in post-mortem brains 
of patients with Huntington Disease, a severe movement disorder characterised 
by degeneration of striatal output neurons (Castro et al., 1998).  
Furthermore, 5-HT1B receptors are also present on neurons projecting from the 
ventral tegmental area to the nucleus accumbens, a dopaminergic pathway 
implicated in the action of cocaine abuse (Cameron and Williams, 1994). In the 
nucleus accumbens, but not in the striatum, increased basal DA levels were 
found, suggesting a role of 5-HT1B receptors in the mesoaccumbal pathway 
(Shippenberg et al., 2000). A role of 5-HT1B receptors in this pathway is supported 
by findings in 5-HT1B receptor knockout mice showing increased propensity to 
self-administer this drug (Rocha et al., 1998) and an enhanced locomotor 
response to cocaine and other dopaminergic drugs (Rocha et al., 1998, Scearce-
Levie et al., 1999).  
The putative selective 5-HT1B receptor CP93129 has been reported to increase 
DA outflow in the PFC (Iyer and Bradberry, 1996), nucleus accumbens (Yan and 
Yan, 2001) and SN (Thorre et al., 1998). In keeping with the effects of CP93129 
on striatal DA outflow of 5-HT1B receptor knockout mice, it would be of interest to 
study the effects of CP93129 in these brain areas of 5-HT1B receptor knockout 
mice. In our study in the mPFC (chapter 3), the initial aim was also to study the 
role of 5-HT1B receptors in DA outflow; however, extracellular DA levels are low in 
this brain area and could not be reliably analyzed in all mice. Extracellular DA 
levels in the PFC are estimated to be about 40 times lower than in the striatum of 
mice (Ihalainen et al., 1999). In the literature, it has been suggested that 5-HT1B 
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receptors modulate hippocampal acetylcholine release in hippocampal 
synaptosomes  (Maura et al., 1986, Sarhan and Fillion, 1999, Bolanos-Jimenez et 
al., 1994) and in the frontal cortex as measured by microdialysis (Consolo et al., 
1996). Most of these studies also used CP93129 to stimulate 5-HT1B receptors, 
therefore it would be also of interest to confirm in 5-HT1B receptor knockout mice 
whether CP93129-induced acetylcholine release in forebrain regions is mediated 
by 5-HT1B receptors. 
 
 
Knockout mouse model versus pharmacological tools 
 
5-HT1B receptor ligands 
In spite of the development of receptor subtype selective compounds, the main 
advantage of a knockout mouse model over pharmacological approaches is the 
selective deletion of one specific receptor. The putative selective 5-HT1B receptor 
agonist CP93129 induced DA outflow to the same extent in knockout and wildtype 
mice (chapter 4). Thus, the 5-HT1B receptor knockout mice revealed that 
CP93129, at a concentration of 50 µM, has affinity for other receptors. A previous 
study in synaptosomes suggested a differential sensitivity of 5-HT1B auto- and 
heteroreceptors for CP93129, and using this technique, no effect of CP93129 on 
evoked striatal DA outflow was found in 5-HT1B receptor knockout (Sarhan and 
Fillion, 1999, Sarhan et al., 2000). Methodological differences undoubtedly exist 
between in vitro synaptosomes and in vivo microdialysis, but our results obtained 
in 5-HT1B receptor knockout mice clearly indicated that the effects of CP93129 on 
DA outflow are not mediated by 5-HT1B receptors.  
The new 5-HT1B receptor antagonist NAS-181 potently augmented the effect of 
fluvoxamine on cortical 5-HT in wildtype, but not in 5-HT1B receptor knockout 
mice, indicating that NAS-181 is a selective 5-HT1B receptor antagonist in mice 
(chapter 3). Furthermore, the potency of NAS-181 was shown as it attenuated the 
decrease in extracellular 5-HT induced by CP93129 (chapter 5) and augmented 
the effect of fluvoxamine in the frontal cortex of rats (chapter 6). Rodent and 
human 5-HT1B receptors are pharmacologically different (see chapter 1) and 
therefore are rodents not the first choice for testing 5-HT1B receptors aimed for 
therapeutic applications in humans. Nevertheless, for fundamental research on 5-
HT1B receptors a selective rodent 5-HT1B receptor antagonist is required as a 
pharmacological tool to discriminate between other 5-HT receptor subtypes and to 
gain more insight in the functional role of 5-HT1B receptors in brain function. It is 
thought that 5-HT1B autoreceptor blockade depends on the prevailing levels of 5-
HT, since administration of a 5-HT1B receptor antagonist alone does not increase 
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5-HT levels. This hypothesis was tested in chapter 6 and the results show that 
there was no additional effect of the 5-HT1B receptor blockade when 5-HT levels 
were enhanced, while only in the presence of a SSRI cortical 5-HT levels were 
augmented by NAS-181. The need of a SSRI to elicit an effect of 5-HT1B 
autoreceptor blockade may be a limitation of the microdialysis technique (see 
below). Nevertheless, a low basal endogenous tone at 5-HT1B sites would fit with 
the finding that basal 5-HT levels are normal in 5-HT1B receptor knockout mice. 
 
Compensatory changes in 5-HT1B receptor knockout mice 
A disadvantage of constitutive knockout mice is the possibility of compensatory 
changes that may have taken place during neurodevelopment. 5-HT1A and 5HT1B 
receptors are functionally mature during the early period of neurodevelopment 
(Hery et al., 1999). It is well known that serotonin is important during 
neurodevelopment, and particularly 5-HT1A receptors are thought to be involved 
during development as a neurotrophic factor (Jacobs and Azmitia, 1992, Azmitia, 
1999). Adaptive changes to compensate for the lack of 5-HT autoregulation at 
nerve terminals may occur at the level of 5-HT release, firing rate, synthesis, re-
uptake, 5-HT1A autoreceptors, 5-HT1D or other (postsynaptic) 5-HT receptors. 
Microdialysis studies have reported normal basal 5-HT levels in 5-HT1B receptor 
knockout mice in the hippocampus, frontal cortex and striatum (this thesis, Trillat 
et al., 1997, Knobelman et al., 2001a). This may indicate that adaptive changes 
have taken place, or that 5-HT1B receptors do not control 5-HT release under 
basal conditions. The dorsal raphe nucleus in 5-HT1B receptor knockout mice 
displays normal activity and firing properties with an equal response to 
somatodendritic 5-HT1A autoreceptor activation as wildtype mice, but was less 
sensitive to citalopram (Evrard et al., 1999). This suggests higher densities of 5-
HT reuptake sites in 5-HT1B knockout mice that was supported by increased 
autoradiographic citalopram labelling in the DRN of these knockouts (Evrard et al., 
1999), although this finding was not confirmed by others (Ase et al., 2001). No 
differences between 5-HT1A receptor binding sites were found in brains of wildtype 
and 5-HT1B receptor knockout mice (Malleret et al., 1999). Following stimulation of 
5-HT1A receptors, no differences were found in corticosterone response or stress-
induced hyperthermia between the two genotypes (Bouwknecht et al., 2002, 
Bouwknecht et al., 2001c). Interestingly, a decrease in G-protein coupling of 5-
HT1A receptors was found in 5-HT1B knockout mice that may indicate a decrease 
in efficiency of 5-HT1A receptors (Ase et al., 2002). Moreover, the 5-HT1B receptor 
knockout mice, however, showed a blunted response to the 5-HT1A receptor 
agonist 8-OH-DPAT in the hippocampus, but not in the striatum (Knobelman et al., 
2001b). The authors proposed a desensitisation of 5-HT1A autoreceptors in the 
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MRN of the knockouts. Interestingly, following locally applied fluvoxamine into the 
hippocampus, a differential dose response was found between the two genotypes, 
suggesting adaptive changes in 5-HT reuptake capacity in 5-HT1B receptor 
knockout mice (chapter 2). Indeed, increased 5-HT transporter densities in the 
hippocampus of 5-HT1B receptor knockout mice are reported (Ase et al., 2001). 
Taken together, the adaptive changes in the regulation of 5-HT release in the 
hippocampus of 5-HT1B receptor knockout mice, support the notion that 5-HT1B 
autoreceptors play a prominent role in 5-HT release in the hippocampus, a brain 
structure mainly innervated by the MRN. Thus, region specific compensatory 
changes are present in the 5-HT1B receptor knockout mice.  
There is substantial evidence that 5-HT1D receptors act as 5-HT autoreceptors in 
the DRN (see for a review Stamford et al., 2000). Relatively little is known about 
the functional role of 5-HT1D receptors localised outside the raphe, but this 
receptor has a distribution similar to 5-HT1B receptors in the forebrain (Bruinvels et 
al., 1993). In 5-HT1B KO mice, 5-HT1D binding sites are unchanged (Malleret et al., 
1999), thus there is as yet no evidence that 5-HT1D receptors compensate for the 
loss of terminal 5-HT1B autoreceptors.  
 
The 5-HT1B receptor knockout mouse as a model to study 5-HT1B receptors 
Despite compensatory changes, the studies in this thesis show that mice lacking 
5-HT1B receptors display increased responses to SSRIs on extracellular 5-HT in 
the hippocampus and prefrontal cortex. The genetic deletion of the 5-HT1B 
receptor has no significant effect on basal 5-HT levels or on behaviour under 
basal conditions. Also, in mice lacking 5-HT1A receptors increased responses to 
SSRIs are found (Knobelman et al., 2001b, He et al., 2001, Parsons et al., 2001) 
and these mice display an anxious behavioural phenotype (Heisler et al., 1998, 
Parks et al., 1998, Olivier et al., 2001, Ramboz et al., 1998). One may expect 
severe changes in 5-HT neurotransmission in the absence of 5-HT autoreceptors, 
however, the phenotype of mice with a genetic deletion of 5-HT1A or 5-HT1B 
receptors is rather mild. Interestingly, a recent study demonstrated an abnormal 
segregation of axons in somatosensory thalamocortical systems of 5-HT 
transporter knockouts and MAOA/5-HT transporter double knockouts. This 
segregation was normalized in MAOA/5-HT1B double and in MAOA/5-HT1B/5-HT 
transporter triple knockouts, indicating that excessive activation of 5-HT1B 
receptors disrupts these projections (Salichon et al., 2001) and these projections 
are impaired in 5-HT1B receptor knockout mice (Upton et al., 2002). Besides a role 
of 5-HT1B receptors in the formation of thalamocortical projections from retinal 
ganglion cells to the superior collicus, it also shows that the genetic deletion of 5-
HT re-uptake sites, MAOA and 5-HT1B receptors results in a viable phenotype. 
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Taken together, these findings suggest a large capacity of the serotonergic 
system for neuroplasticity.  
 
 
Methodological considerations on microdialysis 
 
Extracellular 5-HT 
In vivo microdialysis detects extracellular levels of 5-HT, but this does not 
necessarily reflect the release of 5-HT within the synaptic cleft. A great spill-over 
of 5-HT diffuses out of the synaptic cleft into the extracellular fluid surrounding the 
dialysis probe. As outlined in Chapter 1, 5-HT may act predominantly as a volume 
transmitter. Consistent with the large spill-over of 5-HT outside the synaptic cleft, 
5-HT re-uptake sites and 5-HT1B receptors are mainly found extra-synaptically. 
The amount of extrasynaptic 5-HT in the extracellular space will be diluted as a 
result of re-uptake and enzymatic degradation. Moreover, 5-HT can arise from 
non-neuronal sources such as glial cells, disrupted nerve terminals due to probe 
implantation, blood platelets and blood circulation. Neuronal release of 5-HT 
levels sampled in dialysates from most forebrain areas has been well established 
using the classic criteria of tetrodotoxin and Ca2+ dependency. Changes in 
extracellular 5-HT can readily be detected after stimulation of terminal 
autoreceptors (decrease of 5-HT) or after administration of a SSRI (increase of 5-
HT). By means of microdialysis, however, actual release of 5-HT may not be 
detected. The study presented in chapter 6 suggests that the effect of 5-HT1B 
receptor blockade depend on the presence of a SSRI. When the release of 5-HT 
is increased by blockade of inhibitory 5-HT1B autoreceptors, this increase in 5-HT 
may not be detected as it is rapidly removed from the extracellular space by 5-HT 
reuptake sites before it can reach the microdialysis probe. If the reuptake of 5-HT 
is blocked by a SSRI, the released amount of 5-HT will remain in the extracellular 
fluid and can be detected in the sampled dialysates. Decreases in 5-HT release 
can be detected, as re-uptake does not affect this process.  
 
5-HT in mouse versus rat 
Are there differences in the regulation of 5-HT release between rats and mice? In 
the microdialysis studies presented in this thesis, the sample time was 15 minutes 
in rats and 20 minutes in mice. At the start of the microdialysis studies in mice, the 
5-HT levels detected in 15 minutes samples were too low and therefore the 
sample time was increased to 20 minutes. This may be due to a species 
difference in 5-HT regulation, or this difference may be caused by the small size of 
the mouse brain relative to that of a rat. In rats, a microdialysis probe can be 
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placed either in the ventral or in the dorsal part of the hippocampus, whereas in 
mice the probe is mainly placed in the ventral part, but also in the dorsal part. The 
local administration of 3 and 10 µM fluvoxamine dose-dependently increased 
extracellular 5-HT in rat (dorsal) hippocampus to about 2 and 3-fold of baseline, 
respectively (unpublished observations), whereas in wildtype mice both 0.3 and 
1.0 µM fluvoxamine increased hippocampal 5-HT to 6-fold of baseline (chapter 2). 
These findings support a differential regulation of 5-HT output in the two species. 
As species difference between rat and mice exist, also strain differences in mice 
are known. For the studies in this thesis, 5-HT1B receptor knockout mice on a 
129/Sv background were tested. The genetic background of the knockout mouse 
has been found to be important for the outcome of behavioural studies (Crawley et 
al., 1997, Phillips et al., 1999 , Olivier et al., 2001). There is as yet no evidence for 
such an influence of the genetic background on basal 5-HT levels or for 
pharmacological effects on extracellular 5-HT in 5-HT1B receptor knockout mice. 
Mouse strain-related differences, however, have been reported for basal DA 
dynamics, in the 129/Sv strain, relative to three other mouse strains the basal DA 
uptake was reduced  (He and Shippenberg, 2000). 
 
 
Future directions 
 
The studies presented in this thesis demonstrate an inhibitory role of 5-HT1B 
autoreceptors on extracellular 5-HT following acute locally applied SSRIs, in the 
hippocampus and prefrontal cortex, but not in the dorsal striatum. These findings 
support the notion that 5-HT1B autoreceptors may be an interesting target for 
augmentation strategies of treatment with SSRIs. Further studies are needed to 
elucidate the contribution of region specific effects in the mechanism of action of 
SSRIs. Moreover, detailed studies on the regulation of 5-HT in different brain 
structures may provide more insight in the pathophysiology of different psychiatric 
disorders. Our study could not confirm the previously reported role of striatal 5-
HT1B heteroreceptors on DA outflow in the striatum, because the putative selective 
5-HT1B receptor CP93129 affected DA outflow in the knockouts to the same extent 
as in the wildtype mice. In contrast to 5-HT1B autoreceptors, relatively little is 
known about the functional role of 5-HT1B receptors. Due to restricted selectivity of 
pharmacological tools, the 5-HT1B receptor knockout mouse is an interesting 
model to further explore the functional role of 5-HT1B heteroreceptors. In addition, 
the selective 5-HT1B receptor antagonist NAS-181 may be a valuable 
pharmacological tool to study 5-HT1B receptor in rodents. 
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Summary 
 
The studies described in this thesis explore the role of 5-HT1B receptors in 
serotonin (5-HT) function in rats and in genetically modified mice lacking 5-HT1B 
receptors.  
In chapter 1 relevant literature is reviewed. The serotonergic system is complex 
as 5-HT exerts its function through 14 different receptor subtypes. Serotonergic 
neurons are located in the raphe nuclei and project to brain structures throughout 
the mammalian forebrain, including the hippocampus, frontal cortex and striatum. 
In the mammalian brain, 5-HT1B receptors are expressed either as an inhibitory 5-
HT autoreceptor or as a 5-HT1B heteroreceptor. 5-HT1B autoreceptors are 
localised on serotonergic nerve terminals controlling 5-HT release. 5-HT1B 
heteroreceptors are present on non-serotonergic neurons, suggesting that this 
receptor subtype modulates other neurotransmitters and is involved in a variety of 
functions.  
The serotonergic system is an important target in the treatment of psychiatric 
disorders. Selective serotonin reuptake inhibitors (SSRIs) are widely used in the 
treatment of depression and anxiety disorders, but a clinical problem is the 
delayed therapeutic effect. This delayed onset of action suggests that adaptive 
changes may occur. Previous preclinical studies have indicated a role of both cell 
body 5-HT1A and terminal 5-HT1B autoreceptors in the effects of SSRIs. Moreover, 
dysfunction of 5-HT1B receptors has been associated with aggression, impulsivity, 
alcoholism and drug abuse. More insight in the functional role of 5-HT1B receptors 
contributes to our understanding of this receptor in psychiatric disorders. A 
limitation in research on 5-HT1B receptors has been the relative restricted 
selectivity of 5-HT1B receptor antagonists. Therefore, the generation of 5-HT1B KO 
mouse has provided an interesting model to study 5-HT1B receptors. 
 
In the first part of this thesis, the role of 5-HT1B receptors in the effects of SSRIs 
on 5-HT levels was studied by comparing these effects in wildtype mice with mice 
lacking the 5-HT1B receptor by means of in vivo microdialysis. Activation of 5-HT1B 
autoreceptors reduces the release of 5-HT. Thus in the absence of 5-HT1B 
autoreceptors, increased extracellular 5-HT levels and an increased response to 
SSRIs might be expected. Previous studies have indicated regional effects of 
SSRIs and therefore the effects of SSRI on 5-HT output were examined in 
different brain structures. Upon systemic administration of a SSRI, both cell body 
and terminal 5-HT autoreceptors are activated. To examine the contribution of 
terminal autoreceptors on 5-HT levels, and to circumvent the effects of raphe 5-
HT autoreceptors, a SSRI was locally administered into the brain structures of 
interest by reversed microdialysis. 
Chapter 2 describes a study on the role of 5-HT1B autoreceptors in the effects of 
SSRIs in the hippocampus. Both systemic and local administration of a SSRI 
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resulted in an enhanced 5-HT response in 5-HT1B knockout mice relative to 
wildtypes, indicating that terminal 5-HT1B autoreceptors in the hippocampus limit 
the acute effects of SSRIs.  
No difference was observed between the two genotyes in response to a lower 
concentration of the locally applied SSRI. This finding indicates that 5-HT 
reuptake sites might be increased in the hippocampus of 5-HT1B KO mice to 
compensate for the loss of 5-HT1B autoreceptors. 
In chapter 3 the effects on 5-HT output of locally administered fluvoxamine into 
the medial PFC are described. A locally applied SSRI resulted in an augmented 
response in 5-HT1B KO mice relative to wildtype mice. Blockade of 5-HT1B 
receptors with a selective 5-HT1B receptor antagonist augmented the effect of a 
SSRI on 5-HT output in wildtype mice, further supporting that 5-HT1B 
autoreceptors limit the effects of (local) SSRIs in this brain structure.  
Chapter 4 describes a study on the role of 5-HT1B receptors in the interaction 
between 5-HT and dopamine in the dorsal striatum. The two genotypes showed 
an identical dose-response to local administration of fluvoxamine, indicating that 
5-HT1B receptors do not play a prominent role in the regulation of striatal 5-HT 
release. In contrast, stimulation of 5-HT1B receptors reduced 5-HT levels in 
wildtype mice, indicating that 5-HT1B autoreceptors are functionally present in the 
striatum. A role of striatal 5-HT1B receptors in dopamine outflow could not be 
confirmed in 5-HT1B receptor knockout mice. The putative selective 5-HT1B 
receptor agonist CP93129 increased dopamine outflow in 5-HT1B receptor 
knockout mice to the same extend as in wildtype mice. Therefore, this effect of 
CP93129 cannot be mediated by striatal 5-HT1B heteroreceptors. Possibly the 
effect of CP93129 on dopamine involves 5-HT2, 5-HT3 or 5-HT4 receptors. The 
effect of CP93129 on dopamine outflow was from a neuronal origin (tetrodotoxin 
dependent), but was not attenuated by 5-HT2 receptor blockade. The 5-HT 
releaser fenfluramine and the SSRI fluvoxamine increased 5-HT and dopamine 
levels, but no difference was observed between the genotypes, further supporting 
that 5-HT1B receptors localised in the striatum do not modulate dopamine outflow 
in this brain structure.  
 
In the second part of this thesis, studies are presented on the effects of NAS-181, 
a new selective 5-HT1B receptor antagonist, in rat frontal cortex. In chapter 5, the 
effect on 5-HT levels of NAS-181 was compared with two other 5-HT1B receptor 
antagonists. NAS-181 and GR127935, but not SB224289, attenuated the 
suppressant effect of a 5-HT1B receptor agonist on 5-HT levels. The three 
antagonists reduced 5-HT levels when given alone, but these effects were absent 
in the presence of a SSRI, suggesting some partial agonistic properties of these 
compounds. NAS-181 was found to be a selective 5-HT1B receptor antagonist. 
In chapter 6, the hypothesis was tested whether the effect of a 5-HT1B receptor 
antagonist depends on extracellular 5-HT levels. Previous studies have shown 
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that administration of a 5-HT1B receptor antagonist alone has no effect on 5-HT 
levels. Different strategies were used to enhance extracellular 5-HT levels. NAS-
181 augmented the effect of a locally applied SSRI. Whereas no additional effect 
of NAS-181 was observed when 5-HT levels were increased by depolarization 
induced 5-HT release (with potassium chloride) or by preventing degradation of 5-
HT (with a mono-oxidase inhibitor). Interestingly, in the presence of a SSRI, the 
depolarization induced release of 5-HT was augmented by NAS-181. The data 
provide some evidence that the effect of a 5-HT1B receptor antagonist depends on 
extracellular 5-HT levels, but strongly suggest that additional 5-HT reuptake 
inhibition is required to detect any effect of 5-HT1B receptor antagonists on 5-HT 
levels by means of in vivo microdialysis. 
 
The main results are discussed in chapter 7. The main advantage of a knockout 
model is its selectivity. In addition, the 5-HT1B receptor antagonist NAS-181 can 
be a valuable pharmacological tool to study 5-HT1B receptors in rodents. The 
studies in mice and rats described in this thesis clearly show that 5-HT1B 
autoreceptors limit the acute effects of local administration of a SSRI in the 
hippocampus and frontal cortex, but not in the striatum. These findings support 
the idea that blockade of both 5-HT reuptake sites and 5-HT1B autoreceptors 
might be a potential interesting augmentation strategy for treatment with SSRIs. 
The mice data indicate some evidence for compensatory changes in 5-HT1B KO 
mice, supporting the importance of 5-HT1B receptors in 5-HT neurotransmission. 
In contrast to the well-established role of 5-HT1B autoreceptors, relative little is 
known about 5-HT1B heteroreceptors. The previous reported role of 5-HT1B 
receptors in striatal dopamine release could not be confirmed in the 5-HT1B KO 
mice.  
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Samenvatting 
 
De studies in dit proefschrift onderzoeken de rol van 5-HT1B receptoren in 
serotonine (5-HT) functie in ratten en in genetisch gemodificeerde muizen waarin 
de 5-HT1B receptor uitgeschakeld is.  
In hoofdstuk 1 wordt een overzicht gegeven van de relevante literatuur. Het 
serotonerge systeem is complex, omdat het zijn werking heeft via 14 verschillende 
receptor subtypen. Serotonerge neuronen zijn gelokaliseerd in de raphe kernen 
en projecteren naar hersenstructuren door de gehele voorhersenen, waaronder 
de hippocampus, frontale cortex en striatum. In de hersenen van zoogdieren is de 
5-HT1B receptor aanwezig of als 5-HT autoreceptor of als heteroreceptor. Op 
zenuwuiteinden van serotonerge neuronen zijn 5-HT1B autoreceptoren aanwezig 
die de afgifte van 5-HT reguleren. 5-HT1B heteroreceptoren zijn aanwezig op non-
serotonerge neuronen, wat suggereert dat deze receptoren andere 
neurotransmitters kunnen moduleren en betrokken zijn bij een verscheidenheid 
aan hersenfuncties. 
Het serotonerge systeem is een belangrijk doel in de behandeling van 
psychiatrische stoornissen. Selectieve serotonine heropname remmers (SSRIs) 
worden vaak gebruikt in de behandeling van depressie en angststoornissen, maar 
een klinisch probleem is de vertraagde therapeutische werking. Deze vertraagde 
werking kan mogelijk verklaard worden door het optreden van adaptieve 
veranderingen. Eerdere preklinische studies hebben laten zien dat zowel 5-HT1A 
autoreceptoren op cellichamen als 5-HT1B autoreceptoren op zenuwuiteinden een 
rol spelen in de effecten van SSRIs. Bovendien zijn er aanwijzingen voor 
dysfunctie van 5-HT1B receptoren in agressief gedrag, impulsiviteit, alcoholisme 
en drug misbruik. Onderzoek aan de functie van 5-HT1B receptoren geeft ons 
meer inzicht in de rol van deze receptor in psychiatrische stoornissen. Een 
beperking in het onderzoek aan 5-HT1B receptoren is de relatieve geringe 
selectiviteit van 5-HT1B receptor liganden. Daarom is generatie van genetisch 
gemodificeerde muizen waarin 5-HT1B receptoren zijn uitgeschakeld een 
interessant model om 5-HT1B receptoren te bestuderen. 
 
Het eerste deel van dit proefschrift beschrijft studies waarin in vivo microdialyse is 
toegepast om de rol van 5-HT1B receptoren in de effecten van SSRIs op 5-HT 
afgifte te onderzoeken, door deze effecten in wildtype muizen te vergelijken met 
5-HT1B receptor knockout (KO) muizen. Stimulatie van 5-HT1B autoreceptoren 
resulteert in een afname van de extracellulaire hoeveelheden 5-HT. Dus in de 
afwezigheid van 5-HT1B autoreceptoren kunnen toegenomen 5-HT concentraties 
en een toegenomen respons na toediening van een SSRI verwacht worden. 
Eerdere studies hebben regionale verschillen in de effecten van SSRIs 
aangetoond, daarom zijn verschillende hersenstructuren onderzocht. Na 
systemische toediening van een SSRI worden zowel 5-HT autoreceptoren op 
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cellichamen in de raphe kerne, als 5-HT autoreceptoren op zenuwuiteinden 
gestimuleerd. Om de bijdrage van 5-HT1B receptoren op zenuwuiteinden in SSRI-
effecten op 5-HT te bepalen, en om de effecten van raphe 5-HT1A autoreceptoren 
te omzeilen, werd een SSRI lokaal toegediend in het hersengebied van interesse 
via omgekeerde microdialyse. 
In hoofdstuk 2 wordt de rol van 5-HT1B receptoren in the effecten van SSRIs in 
de hippocampus beschreven. Zowel systemische als lokale toediening van een 
SSRI resulteerden in een verhoogde 5-HT respons in 5-HT1B KO muizen in 
vergelijking met wildtype muizen, wat aantoont dat 5-HT1B autoreceptoren de 
effecten van SSRI op 5-HT afgifte verminderen. Echter, er werd geen verschil 
gevonden tussen wildtype en  5-HT1B KO muizen in de 5-HT respons na een 
lagere concentratie van de lokaal toegediende SSRI. Dit is mogelijk het gevolg 
van een toegenomen aantal 5-HT transporters in de hippocampus van 5-HT1B KO 
muizen ter compensatie van de afwezigheid van de 5-HT1B autoreceptor. 
In hoofdstuk 3 worden de effecten beschreven van een SSRI op 5-HT 
concentraties in de mediale prefrontale cortex. In 5-HT1B KO muizen resulteerde 
de lokale toediening van de SSRI fluvoxamine in een verhoogde 5-HT respons in 
de prefrontale cortex. Blokkade van 5-HT1B receptoren met een selectieve 5-HT1B 
receptor antagonist gaf een versterking van het SSRI effect op 5-HT concentraties 
in wildtype muizen, wat er ook op wijst dat 5-HT1B autoreceptoren de lokale 
effecten van een SSRI in deze hersenstructuur verminderen.  
Hoofdstuk 4 beschrijft een studie naar de rol van 5-HT1B receptoren in de 
interactie tussen 5-HT en dopamine in het dorsale striatum. De dosis respons 
curve na lokale toediening van fluvoxamine was identiek in de twee genotypen, 
wat aangeeft dat 5-HT1B autoreceptoren geen prominente rol spelen in de afgifte 
van 5-HT in het striatum. In tegenstelling, stimulatie van 5-HT1B receptoren met 
CP93129 resulteerde in een verlaging 5-HT concentraties in wildtype muizen, 
maar niet in 5-HT1B KO muizen, wat aangeeft dat 5-HT1B autoreceptoren 
functioneel aanwezig zijn in het striatum. Een rol voor 5-HT1B receptoren in de 
afgifte van DA kon niet worden bevestigd in 5-HT1B KO muizen. De 
veronderstelde selectieve 5-HT1B receptor agonist CP93129 verhoogde dopamine 
concentraties in 5-HT1B KO muizen in dezelfde mate als in wildtype muizen. 
Daarom kan dit effect van CP93129 niet verklaard worden door betrokkenheid van 
5-HT1B heteroreceptoren in het striatum. Mogelijk kan het effect van CP93129 op 
dopamine toegeschreven worden aan betrokkenheid van 5-HT2, 5-HT3 of 5-HT4 
receptoren. Het effect van CP93129 op dopamine was van neuronale origine 
(tetrodotoxin afhankelijk), maar werd niet verminderd door blokkade van 5-HT2 
receptoren. Lokale toediening van de 5-HT releaser fenfluramine of de SSRI 
fluvoxamine verhoogden zowel 5-HT als dopamine concentraties. Er was echter 
geen verschil in deze effecten tussen de twee genotypen, wat er ook op duidt dat 
5-HT1B receptoren in het striatum de afgifte van dopamine in deze hersenstructuur 
niet beïnvloeden.  
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Het tweede deel van dit proefschrift omvat twee studies waarin de effecten van 
NAS-181, een nieuwe selectieve 5-HT1B receptor antagonist, op 5-HT afgifte in de 
frontale cortex van ratten zijn onderzocht. In hoofdstuk 5 wordt een studie 
beschreven waarin het effect van NAS-181 is vergeleken met twee andere 5-HT1B 
receptor antagonisten. De 5-HT1B receptor antagonisten NAS-181 en GR127935, 
maar niet SB224289, konden de een receptor agonist geïnduceerde afname in 5-
HT concentraties gedeeltelijk opheffen. Toediening van de drie receptor 
antagonisten afzonderlijk, in afwezigheid van een SSRI, resulteerde in afname 
van 5-HT concentraties, wat duidt op mogelijke partiële agonistische 
eigenschappen van deze liganden. De data laten zien dat NAS-181 een 
selectieve 5-HT1B receptor antagonist is.  
In hoofdstuk 6 is de hypothese getest of het effect van een 5-HT1B receptor 
antagonist afhankelijk is van de extracellulaire 5-HT concentraties. Eerdere 
studies hebben laten zien dat toediening van alleen een 5-HT1B receptor 
antagonist geen effect heeft op 5-HT concentraties. Daarom zijn in deze studie 
verschillende strategieën gebruikt om de extracellulaire 5-HT concentraties te 
verhogen. NAS-181 gaf een extra 5-HT toename als de 5-HT concentratie werd 
verhoogd door een SSRI. Er werd echter geen effect van NAS-181 gevonden als 
5-HT concentraties werden verhoogd door depolarisatie geïnduceerde 5-HT 
afgifte (met kalium chloride) of door de afbraak van 5-HT te blokkeren (met een 
mono-oxidase remmer). Een interessante bevinding was dat het effect van 
depolarisatie geïnduceerde 5-HT afgifte in aanwezigheid van een SSRI wel door 
NAS-181 kon worden versterkt. De resultaten geven aan dat het effect van een 5-
HT1B receptor antagonist afhankelijk lijkt te zijn van de extracellulaire hoeveelheid 
5-HT, maar duiden er meer op dat 5-HT heropname geblokkeerd moet zijn om 
een effect van 5-HT1B receptor blokkade op 5-HT concentraties te meten met in 
vivo microdialyse.  
 
Hoofdstuk 7 beschrijft de discussie van de voornaamste resultaten. Een 
belangrijk voordeel van een knockout muis model is de selectiviteit. Daarnaast 
kan de selectieve 5-HT1B receptor antagonist NAS-181 een waardevol 
farmacologische middel zijn in onderzoek aan 5-HT1B receptoren in ratten en 
muizen. De studies in ratten en muizen beschreven in dit proefschrift laten 
duidelijk zien dat de acute effecten van een lokaal toegediende SSRI worden 
verminderd door 5-HT1B autoreceptoren in de hippocampus en frontale cortex, 
maar niet in het dorsale striatum. Mogelijk kan blokkade van zowel 5-HT 
heropname en 5-HT1B autoreceptoren een interessante strategie kan zijn om de 
therapeutische werking van SSRI te versnellen. De bevindingen in muizen laten 
ook zien dat er mogelijke aanpassingen zijn in 5-HT1B KO muizen ter compensatie 
van het verlies van 5-HT1B receptoren, wat wijst op het functionele belang van 
deze receptor in 5-HT signaaloverdracht. In tegenstelling tot de algemene 
112  | Samenvatting 
aangenomen rol van 5-HT1B autoreceptoren is er relatief minder bekend over 5-
HT1B heteroreceptoren. Een rol voor 5-HT1B heteroreceptoren in het striatum in de 
afgifte van dopamine kon niet worden bevestigd in de 5-HT1B KO muizen. 
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